PEPTIDE

CATALOG

TAILOR MADE COMPOUNDING

Phone: 1 859 887 0013 | Email: admin@tailormadecompounding.com
 Our Story | 04-05 MK-677 | 36

TABLE OF Peptide Fact Sheets | 06-55

3-Desoxy DHEA | 08
5-Amino-1MQ | 09
Amlexanox | 10
Myristyl | 37
NMN | 38
PEG-MGF | 39
Pentosan Polysulfate | 40
AMT | 11 PNC-27 | 41
Aniracetam | 12 PT-141 | 42
AOD 9604 | 13 PTD-DBM | 43
AOD 9604 + HA | 14 RG3, Methylcobalamin, NAD+ | 44

CONTENTS
BPC-157 | 15 Sarms LGD-4033 | 45
Cerebrolysin | 16 Selank | 46
CJC-1295 | 17 Semax | 47
DHH-B | 18 Tesamorelin | 48
Dihexa | 19 Tesofensine | 49
DSIP | 20 Tetradecylthioacetic Acid (TTA) | 50
Eclomiphene | 21 Thymosin Alpha-1 | 51
Epitalon | 22 Thymosin Beta | 52
FGL (l) | 23 VIP | 53
GHK-Cu | 24 Zinc Thymulin | 54
Glycyrrhetinic Acid & Aminophylline Dosing Charts | 56-62
25
Transdermal Fat Loss Cream
Licensed States | 6 4-65
IGF-1 | 26 TMC App | 66-67
Ipamorelin | 27 Contact Us | 68
iRGD | 28
Kisspeptin-10 | 29
KPV | 30
Leuphasyl | 31
LL-37 | 32
Malanotan II | 33
Met-Enkephalin | 34
MOTS-c | 35
 OUR
Tailor Made Compounding was launched United States. Since the inception of TMC,
in the U.S. in January of 2016. We have we have sourced and compounded over 40
since become a major contributor to unique peptides. We are proud to be the

STORY
peptide medicines in the integrative first in the United States to offer
health space. compounds like CJC 1295, Bremelanotide,
PT 141, BPC-157, and Epitalon and
Through our compounding expertise, continue to introduce new and exciting
knowledge and experience, we have compounds to our formulary.
quickly grown as one of the top
compounding pharmacies in the nation. At Tailor Made, we pride ourselves in being
Together, with our sister pharmacies partners with our practitioners and their
around the world, we have established a staff. That’s why a major part of what we
reputation for working closely with our do involves educating our prescribers on
physicians and are well known for the products we develop, including their
obtaining difficult to source and hard to clinical indications, and dosing. Through
compound pharmaceuticals. Our sister building these relationships and creating
facility and first establishment, Como cutting-edge peptide therapies, we
compounding in Melbourne, has been promise to maintain our status as leaders in
working with peptide therapies for over a the industry. Collectively, all of our
decade. After witnessing the success these locations work to support the same
products were having for both doctors and mission; To positively disrupt medicine
patients in Australia, we saw the demand using innovative technologies through
to bring our compounding expertise to the education and partnership.

Positively disrupting
medicine using
innovative technology
04 05
 PEPTIDE
FACT
SHEETS
At Tailor Made Compounding, we want you to have all the required information
to understand the products we offer. Our peptide fact sheets contain a
description, protocol, and clinical reasearch for each product.

If you have any further questions please reach out to us:

Phone: 1 859 887 0013

Email: admin@tailormadecompounding.com

06 07
 3-Desoxy DHEA 5-amino-1MQ
Purity: >98% (HPLC on request) | Molecular Formula:R1=H, R2=CH3 Purity: >98% (HPLC on request) | Molecular Formula: C10H11N2
Molecular Weight: 288.43 g/mol | Sequence: Non-Peptide Molecular Weight: 159.21 g/mol | Sequence: Non-Peptide

DESCRIPTION: DESCRIPTION:
3-Desoxy DHEA is a competitive aromatase aromatase inhibition only occurs while 3-Desoxy 5-amino-1MQ is a small, selective, membrane permeable to prevent adipogenesis and type II diabetes and reverse
inhibitor for use in controlling estrogen and DHEA is present in the body. 3-Desoxy DHEA molecule that is an inhibitor of nicotinamide diet-induced obesity as a result of increased intracellular
N-methyltransferase (NNMT), a cytosolic enzyme that NAD+ and SAM.
increasing endogenous testosterone production. is a relatively quickly metabolized compound plays a role in cellular metabolism and energy In a study using diet-induced obsese mice fed a high fat
This compound is shown to potently reduce and has an excellent potency with IC50 and Ki homeostasis. NNMT has been found to be up-regualted diet, the effects of 5-amino-1MQ on obesity measures and
aromatase activity through binding to the values. 3-Desoxy DHEA offers you a new option in white adipose tissue of mice compared to other tissues, plasma lipid were evaluated. After 11 days, mice treated
enzyme and blocking access to endogenous for estrogen control and natural testosterone thus, NNMT is an ideal target for anti-obesity medication. with 5-amino-1MQ lost weight, exhibited a decrease in
estrogen precursors (androstenedione, elevation along with a high potency coupled with 5-amino-1MQ is a derivative of methylquinolinium (MQ) white adipose mass and cholesterol levels, and displayed
TAILOR MADE COMPOUNDING

which has exhibited a high efficacy in NNMT inhibition, reduced lipogenesis. The results of this study validate
testosterone). The competitive inhibition offers a better dose control. cell viability, and membrane permeability. It did not have NNMT as a practical target to treat obesity and related
more short term solution to estrogen control, as any effect on the activity of any other enzymes in the metabolic conditions and support the development of an
relevant metabolic cycles, therefore reducing the risks of NNMT inhibitor therapeutics to reverse diet-induced
PROTOCOL: potential side effects. This NNMT inhibitor could be used obesity.

Content & Potency: 100mg capsules provided in quantity of 30.

Suggested dosage: Take 1 capsule by mouth once daily. PROTOCOL:
Content & Potency: 10ml at 300mg/ml
CLINICAL RESEARCH: Suggested dosage: 150mcg (.5ml) daily for 20 days 30 minutes after oral administration of NAD+
precursor
What is desoxy-DHEA and How Does it Work?
Although Desoxy DHEA is an effective competitive
inhibitor of aromatase it is not nearly as potent as SERMs
selected in vitro data. Competitive aromatase inhibition
works differently than suicide substrate inhibition, which is CLINICAL RESEARCH:
or other steroidal and non-steroidal suicide inhibitors. The the mode of action through which other over the Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat
structure- activity relationships mentioned are not counter aromatase inhibitors such as 6-OXO and ATD diet-induced obesity in mice
comprehensive as there undoubtedly exists additional work. Competitive inhibition offers a more short term
There is a critical need for new mechanism-of-action drugs that primary amine substitutions displayed high permeability from
structural manipulations that occur to further enhance solution to estrogen control, as aromatase inhibition only
reduce the burden of obesity and associated chronic metabolic passive and active transport across membranes. Importantly,
aromatase anity. Therefore, it is NOT an appropriate occurs while Desoxy DHEA is present in the body. Desoxy comorbidities. A potentially novel target to treat obesity and type methylquinolinium analogues displayed high selectivity, not
replacement to prescription compounds when heavy DHEA is a relatively quickly metabolized compound. So 2 diabetes is nicotinamide-N-methyltransferase (NNMT), a inhibiting related SAM-dependent methyltransferases or enzymes
aromatase inhibition is required. It does however, offer a with Desoxy DHEA Tailor Made offers you a new option cytosolic enzyme with newly identified roles in cellular in the NAD+ salvage pathway. NNMT inhibitors reduced
cost-effective, safe, and legal method of estrogen for estrogen control. metabolism and energy homeostasis. To validate NNMT as an intracellular 1-MNA, increased intracellular NAD+ and
management as validated by independent lab tests and anti-obesity drug target, we investigated the permeability, selectiv- S-(5’-adenosyl)-L-methionine (SAM), and suppressed lipogenesis
ity, mechanistic, and physiological properties of a series of small in adipocytes. Treatment of diet-induced obese mice
molecule NNMT inhibitors. Membrane permeability of NNMT systemically with a potent NNMT inhibitor significantly reduced
Ben Esgro, BS,CSCS,CISS
inhibitors was characterized using parallel artificial body weight and white adipose mass, decreased adipocyte size,
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. membrane permeability and Caco-2 cell assays. Selectivity was and lowered plasma total cholesterol levels. Notably,
tested against structurally-related methyltransferases and administration of NNMT inhibitors did not impact total food
nicotinamide adenine dinucleotide (NAD+) salvage pathway intake nor produce any observable adverse effects. These results
enzymes. Effects of NNMT inhibitors on lipogenesis and support development of small molecule NNMT inhibitors as
intracellular levels of metabolites, including NNMT reaction therapeutics to reverse diet-induced obesity and validate NNMT
product 1- methylnicotinamide (1-MNA) were evaluated in as a viable target to treat obesity and related metabolic
cultured adipocytes. Effects of a potent NNMT inhibitor on conditions. Increased flux of key cellular energy regulators,
obesity measures and plasma lipid were assessed in diet-induced including NAD+and SAM, may potentially define the therapeutic
obese mice fed a high-fat diet. Methylquinolinium scaffolds with mechanism-of-action of NNMT inhibitors.

Harshini Neelakantan, Virginia Vance, Michael D. Wetzel, Hua-Yu Leo Wang, Stanton F. McHardy, Celeste C. Finnerty, Jonathan D. Hommel, Stanley
J. Watowich

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
08 09
 Amlexanox Ammonium
Purity: >98% (HPLC on request) | Molecular Formula: C16H14N2O4
Molecular Weight: 298.3 g/mol | Sequence: Non-Peptide Tetrathiomolybdate (TBM)
DESCRIPTION: Purity: >98% (HPLC on request) | Molecular Formula: H8N2M0S4
Amlexanox is an anti-inflammatory and anti- shown to selectively inhibit TBK1 and IKK-ε, Molecular Weight: 260.28 g/mol | Sequence: Non-Peptide
allergic compound which has traditionally been producing reversible weight loss and improved
used to treat ulcers by reducing healing time and insulin sensitivity, It is through this mechanism DESCRIPTION:
pain. It has multiple mechanisms of action such that it has produced substantial results in terms Ammonium tetrathiomolybdate (TM) was promising treatment for cancer. Copper is
as inhibiting inflammation by inhibiting the of reducing HbA1C levels and increase insulin developed as a non-toxic treatment for Wilson’s involved in turning on the growth of new blood
release of histamine and leukotrienes. It has been sensitivity. disease, which is a condition that results in vessels that tumors depend on for growth. By
copper buildup in the body. Tetrathiomolybdate depriving the tumors of the copper supply that

TAILOR MADE COMPOUNDING

PROTOCOL: binds both food copper and endogenously is needed for new blood vessels, the growth may
Content & Potency: 40mg capsules provided in a quantity of 90. produced copper and prevents their absorption be slowed or stabilized. It has also been shown to
Suggested dosage: Take one capsule by mouth 3 times daily. when taken with food. When taken without food target the copper transporter ATP7A and
it enters the blood and binds with available enhance the sensitivity of breast cancer to
CLINICAL RESEARCH: copper to prevent it being used by cells.
Tetrathiomolybdate has also shown to be a
Cisplatin treatment, as well as, decreasing the
development of resistance to cisplatin.
Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes.
Numerous studies indicate an inflammatory link between
obesity and type 2 diabetes. The inflammatory kinases
fructosamine. Interestingly, a subset of drug responders also
exhibited improvements in insulin sensitivity and hepatic
PROTOCOL:
IKKε and TBK1 are elevated in obesity; their inhibition in steatosis. This subgroup was characterized by a distinct Content & Potency: 40mg capsules provided in a quantity of 90.
obese mice reduces weight, insulin resistance, fatty liver and inflammatory gene expression signature from biopsied Suggested dosage: Take one capsule by mouth three times daily between meals.
inflammation. Here we studied amlexanox, an inhibitor of subcutaneous fat at baseline. They also exhibited a unique

CLINICAL RESEARCH:
IKKε/TBK1, in a proof-of-concept randomized, double pattern of gene expression changes in response to
blind, placebo-controlled study of 42 obese patients with amlexanox, consistent with increased energy expenditure.
type 2 diabetes and nonalcoholic fatty liver disease. Together, these data suggest that IKKε/TBK1 inhibitors Ammonium Tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast
Treatment of patients with amlexanox produced a may be effective therapies for metabolic disease in an cancer to cisplatin.
statistically significant reduction in Hemoglobin A1c and identifiable subset of patients.
Cisplatin is an effective breast cancer drug but resistance decreased cell proliferation as compared to mono-treat-
often develops over prolonged chemotherapy. Therefore, we ment with cisplatin or TM. Cisplatin/TM treatment of
Oral, Elif A et al. “Inhibition of IKKε and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.” Cell metabolism 26 1
(2017): 157-170.e7 . performed a candidate approach RNAi screen in cisplatin- resistant tumors reduced ATP7A protein levels,
combination with cisplatin treatment to identify molecular attenuated cisplatin sequestering by ATP7A, increased
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. pathways conferring survival advantages. The screen nuclear availability of cisplatin, and subsequently enhanced
identified ATP7A as a therapeutic target. ATP7A is a DNA damage and apoptosis. Microarray analysis of gene
copper ATPase transporter responsible for intercellular ontology pathways that responded uniquely to cisplatin/
movement and sequestering of cisplatin. Pharmaceutical TM double treatment depicted changes in cell cycle
replacement for ATP7A by ammonium tetrathiomolybdate regulation, specifically in the G1/S transition. These
(TM) enhanced cisplatin treatment in breast cancer cells. findings offer the potential to combat platinum-resistant
Allograft and xenograft models in athymic nude mice tumors and sensitize patients to conventional breast cancer
treated with cisplatin/TM exhibited retarded tumor treatment by identifying and targeting the resistant tumors’
growth, reduced accumulation of cancer stem cells and unique molecular adaptations.

Chisholm, Cristine & Wang, Haitao & Hang-Heng Wong, Ada & Vazquez-Ortiz, Guelaguetza & Chen, Weiping & Xu, Xiaoling & Deng, Chu-Xia.
(2016). Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin.
Oncotarget.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

10 11
 Aniracetam AOD 9604
Purity: >98% (HPLC on request) | Molecular Formula: C12H13NO3
Molecular Weight: 219.237 g/mol | Sequence: Non-Peptide Purity: >98% (HPLC on request) | Molecular Formula: C78H123N23O23S2
Molar Weight: 1815.1 | Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-
DESCRIPTION: Gly-Phe

Aniracetam employs a similar method of action effects. It completes this action without causing DESCRIPTION:
to other racetams. It has been shown to sedation and the anxiolytic benefit of the
AOD 9604 is a modified form of amino acids 176-191 amount of fat mass. However, in phase three clinical trials
specifically stimulate the AMPA receptor site. The substance has been extensively studied in animal of the GH proteins. Investigators at Monash University the peptide didn’t mean its confidence interval. Instead, it
AMPA receptor is the most common glutamate- models. This anxiolytic response is believed to be discovered that the fat-reducing effects of GH appear to be is now being studied for its effect on bone and cartilage.
activated receptor associated with the Central caused in part, by activation of the D2 and D3 controlled by a small region near one end of the GH AOD 9604 possesses many other regenerative properties
Nervous System and its functions. AMPA dopamine receptors. Nicotinic Ach receptor molecule. This region, which consists of amino acids 176- associated with growth hormone. Currently, trials are
receptors play a role in learning and memory activation is also believed to contribute to 191, is less than 10% of the total size of the GH Molecule underway to show the application of AOD 9604 in
and appears to have no effect on growth or insulin osteoarthritis, Hypercholesterolemia, bone and cartilage
formation. anxiolytic effects and nootropic effects as well.
TAILOR MADE COMPOUNDING

resistance. This hypothesis was proven in animals to a repair & pain. AOD 9604 has an excellent safety profile,
Aniracetam seems to have a higher affinity with Additionally, Aniracetam seems to enact on tremendous degree with specimen losing a significant recently obtaining Human GRAS status in the USA.
the AMPA receptors than other racemic the 5-HTP(2a) receptor which helps to process
compounds. Another interesting action of
Aniracetam is the observed anxiety- reducing
Serotonin and may further advance anxiolytic/
antidepressant functions.
PROTOCOL:
Content & Potency: 1200mcg/ml subcutaneous injectable provided in a 5ml vial.
PROTOCOL: Suggested dosage: Inject 0.25ml subcutaneously once daily for 20 days.

Content & Potency: 375mg capsules provided in a quantity of 60.

Suggested dosage: Take two capsules by mouth with food.
CLINICAL RESEARCH:
Safety and Tolerability of the Hexadecapeptide AOD 9604 in humans

CLINICAL RESEARCH: Background: The human growth hormone (hGH) has

fat loss properties making it a potential candidate to treat
Results: AOD 9604 had no effect on serum IGF-1 levels,
which confirms the hypothesis that AOD 9604 does not
Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase Inhibitors, in Patients obesity. AOD 9604 is a peptide fragment of the act via IGF-1. Results of oral glucose tolerance test
with Cognitive Impairment: A Comparative Open Study C-terminus of hGH (Tyr-hGH177-191), which harbors demonstrated that, in contrast with hGH, AOD 9604
In the present study, we aimed to evaluate the efficacy of comparison between aniracetam and ChEls in patients with the fat reducing activity of hGH, without its negative has no negative effect on carbohydrate metabolism. There
aniracetam, either as monotherapy or combined with relatively mild dementia (15 ≤ MMSE ≤ 25) revealed a effects. In this paper the safety data of AOD 9604 were no anti-AOD 9604 antibodies detected in any of the
cholinesterase inhibitors (ChEls), in terms of several significantly better cognitive performance with obtained in clinical trials are summarized. patients selected for antibody assay. In none of the studies
neuropsychological parameters, in a considerable number aniracetam at 6 months and improved functionality at 3 did a withdrawal or serious adverse event occur related to
of patients with dementia. In our prospective, open-label months. Comparing aniracetam monotherapy with Methods: Six randomized, double-blind, placebo-cotrolled intake of AOD 9604.
study, we enrolled a total of 276 patients (mean age 71 ± 8 combined treatment in the same population, aniracetam trials were performed with AOD 9604. Special focus was
years, 95 males) with cognitive disorders. Our study performed better in the cognitive scale at 6 months, and given to undesired effects associated with hGH treatment: Conclusion: AOD 9604 displayed a very good safety and
population comprised four groups: no treatment group displayed a notable tendency for enhanced mood at 12 increases in IGF-1 levels, insulin resistance, and impaired tolerability profile indistinguishable from placebo. AOD
(n = 75), aniracetam monotherapy group (n = 58), ChEIs months and improved functionality at 6 months. glucose tolerance. Blood samples were analyzed for presence 9604 did not result in any of the adverse effects associated
monotherapy group (n = 68), and group of combined Conclusions: Our findings indicate that aniracetam (a noo- of antiAOD 9604 antibodies to exclude immunogenicity. with full-length hGH treatment
treatment (n = 68). Patients were examined with validated tropic compound with glutamatergic activity and
neuropsychological tests at baseline, 3, 6, and 12 months of neuroprotective potential) is a promising option for Stiera, Heike et al. “Safety and Tolerability of the Hexadecapeptide AOD 9604 in Humans.” (2013).
treatment. In patients treated with aniracetam, all patients with cognitive deficit of mild severity. It preserved
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
studied parameters were adequately maintained at 6 and 12 all neuropsychological parameters for at least 12 months,
months, while emotional state was significantly improved and seemed to exert a favorable effect on emotional
at 3 months. In patients treated with ChEIs, we observed a stability of demented patients.
significant cognitive deterioration at 12 months. The

Koliaki, C. C., Messini, C. and Tsolaki, M. (2012), Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase
Inhibitors, in Patients with Cognitive Impairment: A Comparative Open Study*. CNS Neuroscience & Therapeutics, 18: 302-312.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

12 13
 AOD 9604 + HA BPC-157
Purity: >98% (HPLC on request) | Molecular Formula: C78H123N23O23S2 Purity: >98% (HPLC on request) | Molecular Formula: C62H98N16O22
Molecular Weight: 1815.1 g/mol | Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-lle-Glu-Lys- Molecular Weight: 1419.5355 | Sequence: L-Valine,glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-
Phe-Asp-Lys-Ser-Lys-Leu-Lys-LysThr-Glu-Thr-Gin-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thy- prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-
lleGlu-Gin-Glu-Lys-Gin-Ala-Gly-Glu-Ser ;glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyllysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-
L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine
DESCRIPTION:
AOD9604 is a GH fragment which comprised the last differentiation of myoblasts into C2C12 cells; all of which DESCRIPTION:
16 amino acids of the larger growth hormone molecule. are essential for bone, cartilage, and muscle repair. These Pentadecapeptide BPC 157, composed of 15 ulcers. BPC-157 acts systemically in the digestive
Although originally studied for fat loss, further studies have studies indicate that it has stronger therapeutic benefits
amino acids, is a partial sequence of body tract to combat leaky gut, IBS, gastrointestinal
transitioned it’s application for regenerative medicine. In compared to Bone Marrow Aspirate Concentrate (BMAC)
combination with hyaluronic acid (HA), it is now being and Platelet Rich Plasma (PRP) therapy, which have also protection compound (BPC) that is discovered in cramps, and Crohn’s disease.
used to help regenerate hyaline cartilage and is showing been emerging as candidates for osteoarthritis medications. and isolated from human gastric juice. This peptide has been known to exhibit analgesic

TAILOR MADE COMPOUNDING

strong efficacy in the treatment of osteoarthritis. The AOD9604 + HA has proceeded to human WOMAC trials Experimentally it has been demonstrated to characteristics as well. Those who suffer from
combination acts to enhance the differentiation of adipose which allow the combination to be investigated for on an accelerate the healing of many different wounds, discomfort due to muscle sprains, tears and
mesenchymal stem cells into bone, promote proteoglycan osteoarthritis index which considers pain, stiffness, and
including tendon-to-bone healing and superior damage may benefit from treatment with this
and collagen production in chondrocytes, and promote functionality on a variety of scores.
healing of damaged ligaments. peptide. It can also help to aid skin burns at a
Additionally, BPC 157 has shown to protect faster rate by increasing blood flow to damaged
PROTOCOL: organs and aids in the prevention of gastric tissues.
Content & Potency: AOD 1000mcg/ml + HA 10mg/ml intra-articular injectable provided in a 5ml
vial. PROTOCOL:
Suggested dosage: 0.5-0.75m injected intra-articularly by a medical professional once a week for 4
Content & Potency: • Injectable: 2000mcg/ml subcutaneous injectable provided in a 5ml vial.
weeks, then once a month for 5 months.
• Oral: 500mcg capsule provided in a quantity of 30.
• Nasal: 2mg/mL nasal spray in a 3mL bottle
CLINICAL RESEARCH: • Cream: 100mcg/mL transdermal 30g
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
BPC/HOD/GHK-<0 2mg/1mg/2mg/mL 30mL
Suggested dosage: • Injectable: 0.15ml injected subcutaneously every day for 30 days.
Objective: To investigate the effects of AOD9604 intra- Results: Mean gross morphological and histopathological • Oral: 30 capsules at 500mcg. Take one capsule by mouth once daily for 30 days.
articular injections with or without hyaluronic acid (HA) scores were significantly higher in Group 1 than in Groups
in a collagenase-induced knee osteoarthritis (OA) rabbit 2, 3, and 4, and the scores were significantly lower in
model. Group 4 than in Groups 2 and 3. The lameness period in CLINICAL RESEARCH:
Group 4 was significantly shorter than those in Groups 1,
Design: Mature New Zealand white rabbits (n=32) were 2, and 3. The lameness period in Group 1 was significantly The Promoting effect of Pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival,
randomly administered 2 mg collagenase type II twice in longer than those in Groups 2 and 3. and cell migration
each knee joint. Weekly injections of 0.6 mL saline (Group Many growth factors such as epidermal growth factor easily dissolved in water and needs no carrier for its
1), 6 mg HA (Group 2), 0.25 mg AOD9604 (Group 3), Conclusion: Intra-articular AOD9604 injections using (EGF), transforming growth factor-(TGF-), and bone application. Experimentally it was demonstrated to
and 0.25 mg AOD9604 with 6 mg HA (Group 4) were ultrasound guidance enhanced cartilage regeneration, and morphogenetic proteins (BMPs) have been used to enhance the healing of different wounds, such as gastric
administered for 4-7 weeks after the first intra-articular combined AOD9604 and HA injections were more improve the healing of torn tendon in the lab. However, ulcer, skin, cornea, muscle, colon-colon anastomosis,
collagenase injection. The degree of cartilage degeneration effective than HA or AOD9604 injections alone in the the short duration of these easily digested growth factors colocutaneous fistula, and segmental bone defect. It was
was assessed using morphological and histopathological collagenase-induced knee OA rabbit model. hampers their clinical usage. Gastric pentadecapeptide BPC also found to accelerate the healing of transected rat
findings, and the degree of lameness was observed at 8 157 is a partial sequence of human gastric protein BPC, Achilles tendon (12, 29) and medial collateral ligament of
weeks after the first collagenase injection. which has been discovered in and isolated from gastric knee. Currently it is in clinical trials for treating
juice. It is highly stable and resistant to hydrolysis or inflammatory bowel disease.
Beom Kim, Sang & Kwon, Dong & Kwak, Hyun & Shin, Yong & Han, Hyun-Jung & Hwa Lee, Jong & Choi, Seok Hwa. (2010). Additive Effects of enzyme digestion, even in the gastric juice. Besides, it is
Intra-articular Injection of Growth Hormone and Hyaluronic Acid in Rabbit Model of Collagenase-induced Osteoarthritis. Journal of Korean medical
science. 25.
Chung-Hsun Chang, Wen-Chung,Tsai Miao-Sui Lin, Ya-Hui Hsu, and Jong-Hwei Su Pang
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

14 15
 Cerebrolysin CJC-1295
Purity: >99% (HPLC on request) Purity: >98% (HPLC on request) | Molecular Formula: C165H269N47O46
Molecular Weight: 3647.15 | Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-
DESCRIPTION: Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Cerebrolysin (synonym FPE 1070) is a nootropic

drug which consists of low-molecular peptides
neurotrophic action similar to nerve growth
factors, which cause peripheral and central
DESCRIPTION:
CJC 1295 stimulates growth hormone release via binding version of CJC most use clinically. This version of the CJC
which possesses neuroprotective and neuronal stimulation. It improves efficiency to the pituitary. This peptide directly mimics the 1295 outperforms the older and outdated GHRHs such as
neurotrophic repair properties. The active within the brain’s aerobic metabolic processes endogenous Growth Hormone Releasing Hormone Sermorelin. The half-life of Sermorelin ranges from 8-12
fragment of Cerebrolysin is made of proteins and improves intracellular peptide synthesis. The (GHRH) typically secreted by the hypothalamus. CJC minutes, whereas the half-life of CJC 1295 extends to 30
with very low molecular masses that do not neuroprotective properties of this nootropic agent 1295 comes in 2 chemical forms. One includes a binding minutes.
exceed 10.000 daltons. This means they can help to shield neurons from lactocidosis, to group called DAC, or Drug Activity Complex. The DAC
bind to serum albumin and significantly increases half life. As a result of better stimulation and release you see many
penetrate the blood-brain (or blood-SCF) barrier prevent the formation of free radicals, and have However, for many reasons, this is not the preferred clinical results including fat loss, increases lean muscle
TAILOR MADE COMPOUNDING

and reach neurons directly, making the drug able been studied in Parkinson’s, Alzheimer’s, MS, product for many patients clinically. mass, better lipid profiles, better deep wave sleep and
to show organo-specific combined effects towards ALS, TBI, and stroke. increased repair and recovery. Use in combination with
the brain. Cerebrolysin has been proven to have Instead, the tetrasubstituted 29 amino acid modified Ipamorelin, the CJC is one of the most widely prescribed
growth releasing factor often called Mod-GRF is the products.

PROTOCOL:
PROTOCOL:
Content & Potency: 215.2mg/mL x 10mL x 4 vials : ready-to-inject subcutaneously
Content & Potency: 2000mcg/ml subcutaneous injection provided in a 2ml vial.
Suggested dosage: Inject 1ml daily for over a 40 week course. Suggested dosage: Inject 0.10ml subcutaneously 5 out of 7 nights of the week before bedtime on an empty stomach.

CLINICAL RESEARCH: ***We suggest using the CJC 1295 in combination with Ipamorelin as it provides a synergistic effect, generating five
times the benefits of using the CJC 1295 or Ipamorelin alone. The combination
Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic allows for a maximized release of GH because CJC 1295 and Ipamorelin have different mechanisms of action and work
agent on different receptors (GHRH-R & Ghrelin-R).
Cerebrolysin (Cere) is a compound with neurotrophic onset of dementia, and the number of patients with
activity. It has been shown to be effective in the treatment
of Alzheimer’s disease (AD) in earlier trials. In this
hallucinations. At week 12 there was a significant difference
on the CIBIC + (p=0.033) in favor of Cere. The number CLINICAL RESEARCH:
multicenter, randomized, double-blind, placebo-controlled, of CIBIC+ responders (score < 4), was significantly higher Factor I Secretion by CJC 1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
parallel-group study, patients were injected intravenously (p=0.007), with 68 (76%) in the Cere group and 51 (57%)
Context: Therapeutic use of GHRH to enhance GH secretion is standard pharmacokinetic parameters were used for CJC 1295.
with placebo or 30mL Cere five days per week for four in the placebo group. Trends were noted in the Disability limited by its short duration of action. Results: After a single injection of CJC 1295, there were dose
weeks. Effects on cognition and global function were Assessment in Dementia scale and the Cornell Depression Objective: The objective of this study was to examine the dependent increase in mean plasma GH
evaluated with the Alzheimer Disease Assessment Scale – Scale. Adverse events were recorded in 73% of placebo and pharmacokinetic profile, pharmacodynamic effects, and safety of concentrations by 2- to 10-fold for 6 d or more and in mean
Cognitive Subscale (ADAS-Cog) and the Clinician 64% of Cere patients. Most common adverse events were CJC 1295, a long-acting GHRH analog. plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d. The
Interview based Impression of Change with Caregiver headaches, dizziness, weight loss and anxiety. Conclusions: Design: The study design was two randomized, placebo- estimated half-life of CJC 1295 was 5.8-8.1 d. After multiple CJC
Input scale (CIBIC+) 4, 12, 24 weeks after the beginning Cere treatment was well tolerated and resulted in controlled, double blind, ascending dose trials with durations of 1295 doses, mean IGF-I levels remained above baseline for up to
of the injections. 192 patients were enrolled, 95 were significant improvements in the global score two months 28 and 49 d. 28 d. No serious adverse reactions were reported.
randomized to placebo, and 97 to Cere. At baseline, there after the end of active treatment. Setting: The study was performed at two investigational sites. Conclusions: Subcutaneous administration of CJC 1295 resulted
Participants: Healthy subjects, ages 21–61 yr, were studied. in sustained, dose-dependent increases in GH and IGF-I levels in
was a significant difference between groups for age, age of
Interventions: CJC 1295 or placebo was administered sc in one of healthy adults and was safe and relatively well tolerated,
four ascendings single doses in the first study and in two or three particularly at doses of 30 or 60 ug/kg. There was evidence of
M. Panisset, S. Gauthier, H. Moessler, M. Windisch weekly or biweekly doses in the second study. a cumulative effect after multiple doses. These data support the
Main Outcome Measures: The main outcome measures were potential utility of CJC 1295 as a therapeutic agent.
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. peak concentrations and area under the curve of GH and IGF-I;

Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, Lawrence A. Frohman, Prolonged Stimulation of Growth
Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults, The
Journal of Clinical Endocrinology & Metabolism, Volume 91, Issue 3, 1 March 2006, Pages 799–805, https://doi.org/10.1210/jc.2005-1536

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
16 17
 DHH-B Dihexa
Purity: >98% (HPLC on request) | Molecular Formula: C24H31NO4 Purity: >98% (HPLC on request) | Molecular Formula: C27H44N4O5
Molecular Weight: 397.51 g/mol | Sequence: Non- peptide Molecular Weight: 504.672 g/mol | Sequence: Non-peptide

DESCRIPTION: DESCRIPTION:
DHH-B, dihydrohonokiol-B, is a natural States. These anxiolytics have many well-known Dihexa is a peptide variant derived from and memory in animal models when
supplement which has anxiolytic-effects. side effects including motor function and more. angiotensin IV which has been found to potently administered centrally or peripherally. In an assay
Treatment with DHH-B does not cause any That being said, this product has the potential to improve cognitive function in animal models of of neurotrophic activity, Dihexa was found to
significant changes in motor activity or muscle help people transition from benzodiazepines to disease such as Alzheimer’s. Angiotensin IV is a be seven orders of magnitude more potent than
relaxation. Benzodiazepines are some of the most DHH-B or act as an alternative to derivative of the potent vasoconstrictor BDNF. It could possibly help in the repair of the
commonly prescribed medications in the United benzodiazepines. angiotensin II and has been shown to enhance brain and nerves in neurological disease.

TAILOR MADE COMPOUNDING

acquisition, consolidation, and recall of learning
PROTOCOL:
Content & Potency: 30, 7.5mg capsules PROTOCOL:
Suggested dosage: Take 1-2 capsules as needed Content & Potency: • Cream: 20mg/ml transdermal cream provided in a 30ml transdermal
applicator.
CLINICAL RESEARCH: • Oral: 1mg or 2mg capsules
Suggested dosage: • Cream: Apply 0.5-1.0ml (2-4 clicks) to inner forearms once daily, rub in
Comparative assessment of the anxiolytic-like activities of honokiol and derivatives
until absorbed.
A Department of Neuropsychopharmacology derivative of honokiol [30-(2-propenyl)-5- • Oral: Taken once daily.
(Tsumura), Gunma University School of Medicine, propyl-(1,10-biphenyl)-2,40-diol] exhibited
3-39-22 Showa-machi, Maebashi, Gunma 371-8511,
Japan Research Laboratories, Tsumura and Co.,
significant anxiolytic-like activity at 0.04 mg/kg.
Following oral administration of 1 mg/kg of this CLINICAL RESEARCH:
Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan analog, anxiolytic-like activity was clearly evident at 1 The Procognitive and Synaptogenic Effects of Angiotensin IV– Derived Peptides Are Dependent on Activation of
Department of Biochemistry, The University of Texas h, peaked at 3 h, and remained significant for longer the Hepatocyte Growth Factor / c-Met System
Health Science Center at San Antonio, San Antonio, than 4 h after treatment. Combined administration A subset of angiotensin IV (AngIV)–related molecules are to hepatocyte growth factor (HGF) and both dihexa and its
TX, USA of the derivative with diazepam led to enhanced known to possess procognitive/antidementia properties and parent compound Norleucine 1-AngIV (Nle1-AngIV)
anxiolytic-like efficacy. Moreover, as with diazepam, have been considered as templates for potential induce c-Met phosphorylation in the presence of
Honokiol has previously been shown to be an the anxiolytic-like effect of the analog was reduced by therapeutics. However, this potential has not been realized subthreshold concentrations of HGF and augment HGF-
effective anxiolytic-like agent in mice when flumazenil. In contrast, bicuculline, a GABAA because of two factors: 1) a lack of blood- brain dependent cell scattering. Further, dihexa and Nle1-AngIV
administered for 7 days at 0.2 mg/kg/day prior to antagonist, had no effect on the activity of the barrier– penetrant analogs, and 2) the absence of a induce hippocampal spinogenesis and synaptogenesis
validated mechanism of action. The pharmacokinetic similar to HGF itself. These actions were inhibited by
evaluation in an elevated plus-maze, while 20 mg/kg derivative. Taken together, these results suggest that
barrier has recently been overcome with the synthesis of an HGF antagonist and a short hairpin RNA directed at
is required for efficacy as a single oral dose. The aim this analog of honokiol acts at the benzodiazepine
the orally active, blood-brain barrier–permeable analog c-Met. Most importantly, the procognitive/antidementia
of this study was to find analogs of honokiol that are recognition site of the GABAA ± benzodiazepine N-hexanoic-tyrosine-isoleucine-(6) aminohexanoic amide capacity of orally delivered dihexa was blocked by an HGF
more effective for acute administration. Among the receptor complex. (dihexa). Therefore, the goal of this study was to elucidate antagonist delivered intracerebroventricularly as measured
eight analogs evaluated, one partially reduced the mechanism that underlies dihexa’s procognitive activity. using the Morris water maze task of spatial learning.
Here, we demonstrate that dihexa binds with high affinity
Hisashi Kuribaraa, Eiko Kishia, Masayuki Kimurab, Susan T. Weintraubc, Yuji Maruyamaa,*
Benoist, Caroline C et al. “The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. growth factor/c-met system.” The Journal of pharmacology and experimental therapeutics vol. 351,2 (2014): 390-402.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

18 19
 DSIP Enclomiphene
Purity: >98% (HPLC on request) | Molecular Formula: C35H48N10O15
Molecular Weight: 848.81 | Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu Purity: >98% (HPLC on request) | Molecular Formula: C26H28CINO
Molecular Weight: 405.966 g/mol | Sequence: Non-peptide
DESCRIPTION:
DSIP is a well-known neuromodulator and pronounced stress protective action and decreases DESCRIPTION:
natural somnogenic nonapeptide with many stress-induced metabolic and functional disorders Enclomiphene is used in the process of treating gonadotropin secretion and gonadal production
other physiological functions. It is typically found in human and animal organisms exposed to a male hypogonadism (lower function of the of testosterone. Enclomiphene has the potential
in the brain and easily passes the blood-brain variety of stresses. Some of the effects of the reproductive organs) and is a single isomer with to help the reproductive status in men and
barrier. It is mainly prescribed for the treatment peptide are accomplished through the pure estrogen antagonism. Enclomiphene is a improve metabolic profiles. It is a single isoform
of pain conditions, alcohol and opioid modulating action on central regulatory non-steroidal selective estrogen receptor of the more abundant clomiphene and has much
withdrawal, CRH and stress-related symptoms, processes, owing to the systemic antioxidant modulator (SERM) and acts by increasing fewer side effects.
TAILOR MADE COMPOUNDING

low testosterone (via stimulation of LH), and action, the modulating influence on the activity
even sometimes as an antioxidant and anti- of GABAergic, glutamatergic, and other neuronal
oncogenic protein. It has been discovered and systems. It also works on the expression of early PROTOCOL:
heavily studied for over 40 years, yet, the response genes in brain structures, and on the Content & Potency: 25mg capsules provided in a quantity of 30.
mechanism of action is still complex and not well activity of biosynthetic and proteolytic Suggested dosage: Take one capsule by mouth once daily.
understood. The results of studies of DSIP and processes. DSIP has traditionally been dosed as
its analogues over a period of 30 years since its an IV infusion, however, it can be given CLINICAL RESEARCH:
discovery enable one to state with confidence that subcutaneously as well. Traditional doses have
Enclomiphene citrate stimulates testosterone production while p-eventing oligospermia: a randomized phase II
DSIP is a unique member of the family of been 100mcg. clinical trial comparing topical testosterone.
peptide neuromodulators. It exhibits a
Objective: To determine the effect of enclomiphene citrate
in men with secondary hypogonadism. Results: A total of 113 men received 3 months of
PROTOCOL: treatment, and 73 completed the study and provided both
Methods: iws randomized phase IIB study enrolled 124 baseline and at least 1 seman sample at the end of the study.
Content & Potency: 1000mcg/ml subcutaneous injectable provided in a 3ml vial. men with a morning serum T level of <250 ng/dL on 2 All 3 active treatment groups showed significantly increased
Suggested dosage: Inject 0.1ml subcutaneously once daily 2-3 times per week. occasions. e subjects were randomized to one of two doses in total testosterone level from baseline compared with
of enclomiphene citrate (12.5-mg or 25-mg), 1% topical placebo, with no statistically significant difference in
CLINICAL RESEARCH: testosterone, or placebo. Hormone levels of LH, FSH, and
T and seman level were measured before, during and aer 3
testosterone levels found between the active treatment
groups compared with placebo.
DSIP-more than a sleep peptide? months of treatment.
In several species DSIP at low doses has been shown to some penetration of the blood-brain barrier in essentially
promote sleep. Although its physiological role remains to intact form. Concepts applicable to one neuropeptide, Wiehle RD, Fontenot GK, Wike J, et al. ZA-203 Clinical Study Group. Fertil Steril. 2014; 102(3): 720-727.
be clarified, DSIP illustrates several concepts applicable to therefore, appear to be applicable to others. In this article A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
other brain peptides. These include the bell- shaped dose- Abba Kastin and colleagues review the known effects of
response curve, central effects after peripheral DSIP and argue that more work needs to be carried out
administration, a delayed and prolonged time course, and before it can be labelled functionally.

J. Kastin, Abba & A. Olson, Gayle & V. Schally, Andrew & H. Coy, David. (1980). DSIP — more than a sleep peptide?. Trends in Neurosciences -
TRENDS NEUROSCI. 3. 163-165.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

20 21
 Epitalon FGL(l)
Purity: >98% (HPLC on request) | Molecular Formula: C16H24N4O10 Purity: >98% (HPLC on request) | Molecular Formula: C71H116N20O25
Molecular Weight: 432.4 g/mol | Sequence: H-Ala-Glu-Asp-Gly-O Molecular Weight: 3432.62 g·mol−1 | Sequence: Glu-Val-Tyr-Val-Val-Ala-Glu-Asn-Gln-Gln-Gly-
Lys-Ser-Lys-Ala
DESCRIPTION:
Epithalon (also known as Epitalon or Epithalone) It is a bio-regulator for the endocrine system, DESCRIPTION:
is the synthetic version of the polypeptide especially for the pineal gland, and has been FGL(L) is a peptide with neurotrophic and by decreasing oxidative stress-induced neuronal
Epithalamin which is naturally produced in shown to lengthen telomeres in human cells. The memory enhancing properties. FGL peptide is a cell death. FGL was also demonstrated to affect
humans. The pineal peptide preparation is mechanisms in Epitalon are a lot more complex variant of the natural neural cell adhesion neuropathological symptoms related to
secreted in the epithalamium-epiphyseal region than just activating telomerase. It reduces lipid molecule. Neural cell adhesion molecule Alzheimer’s disease by inhibiting neuronal
of the brain. Its more prominent tasks are: to oxidation and ROS, along with normalizing T (NCAM) is a membrane-bound glycoprotein degeneration and death.
regulate metabolism in the epiphysis, increase the cell function. It seems to normalize cholesterol expressed on the surface of neuronal and glial

TAILOR MADE COMPOUNDING

sensitivity of hypothalamus to its natural and uric acid, along with prolactin levels. It has cells. FGL(L) was directly created as a fibroblast Its potential effect on memory and
hormonal influences, normalize the function shown promise in restoring pancreatic hormone growth factor receptor agonist. neurodegenerative disease progression have
of the anterior pituitary, regulate the levels function. Additionally, it restored and normalized FG loop (FGL) peptide, that is derived from the excited many people and it was awarded a 60
of gonadotropins and melatonin in the body. melatonin levels in older patients who have lost second F3 module of NCAM has been found to million dollar grant in 2016 for further
Epithalamin increases a person’s resistance to some pineal function due to aging. activate FGFR1. Activating the NCAM–FGFR exploration. In addition to its effects on
emotional stress and also acts as an antioxidant. signaling pathways result in increased neurite neurodegenerative disease, it also has been
outgrowth and survival and leads to its effects in viewed as a targeted treatment for TBI, stroke,
PROTOCOL: memory. In addition to its effects on memory, depression, and general improvement of cognitive
FGL was found to have a positive impact on the function.
Content & Potency: 10mg/ml subcutaneous injection provided in a 5ml vial.
healing of neuronal tissues subjected to ischemia
Suggested dosage: Inject 10mg every 3 days for 15 days - repeat twice yearly.

CLINICAL RESEARCH: PROTOCOL:

Content & Potency: 10mg/ml solution provided in a 3ml vial.
Peptide Geroprotector from the Pituitary Gland Inhibits Rapid Aging of Elderly People:
Results of 15-Year Follow-Up Suggested dosage: Inject 0.1ml subcutaneously daily into the abdomen.

CLINICAL RESEARCH:
The paper presents the results of randomized comparative years) decelerated aging of the cardiovascular system,
study of the efficiency of peptide geroprotector from the prevented age-associated impairment of physical endurance,
pituitary gland in elderly patients with rapidly aging normalized circadian rhythm of melatonin production and A Neural Cell Adhesion Molecule–Derived Fibroblast Growth Factor Receptor Agonist, the FGL-Peptide, Promotes
cardiovascular system. Over three years 39 coronary carbohydrate and lipid metabolism. A significantly lower Early Postnatal Sensorimotor Development and Enhances Social Memory Retention
patients received, in addition to basic therapy, regular mortality in the group of patients treated with epithalamin
courses of epithalamin (peptide drug), while 40 coronary in parallel with basic therapy also indicated a geroprotective Abstract—The neural cell adhesion molecule (NCAM) We here report that the FGL peptide, when administered
patients (control group) received basic therapy alone. effect of the peptide preparation from the pineal gland. belongs to the immunoglobulin (Ig) superfamily and is intranasally to newborn rats, accelerated early postnatal
Long-term treatment with epithalamin (6 courses over 3 composed extracellularly of five Ig-like and two fibronectin development of coordination skills. In adult animals s.c.
type III (F3) modules. It plays a pivotal role in neuronal administration of FGL resulted in a prolonged retention of
development and synaptic plasticity. NCAM signals via a social memory. We found that FGL rapidly penetrated into
O. V. Korkushko, V. Kh. Khavinson*, V. B. Shatilo, and I. A. Antonyk-Sheglova Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol.
151, No. 3, pp. 343-347, March, 2011. direct interaction with the fibroblast growth factor the blood and cerebrospinal fluid after both intranasal and
receptor (FGFR). A 15-amino-acid long peptide, the FG s.c. administration and remained detectable in the fluids for
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. loop (FGL) peptide, that is derived from the second F3 up to 5 hours.
module of NCAM has been found to activate FGFR1.

Echer, T & Novitskaia, V & Berezin, Vladimir & Bock, Elisabeth & Glenthøj, B & Klementiev, B. (2006). A neural cell adhesion molecule-derived
fibroblast growth factor receptor agonist, the FGL-peptide, promotes early postnatal sensorimotor development and enhances social memory retention.
Neuroscience. 141. 1289-99. 10.1016/j.neuroscience.2006.04.059.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

22 23
 GHK-Cu Glycyrrhetinic Acid & Aminophylline
Transdermal Fat Loss Cream
Purity: >98% (HPLC on request) | Molecular Formula: C28H52CuN12O8
Molecular Weight: 748.346 g/mol | Sequence: Non-Peptide Glycyrrhetinic Acid- Purity: >98% | Molecular Formula: C30H46O4
Molecular Weight:470.69 g/mol | Sequence: Non-Peptide
DESCRIPTION: Aminophylline- Purity: >98% | Molecular Formula: C16H24N10O4
GHK-Cu is a naturally occurring copper complex feedback signal that is generated after tissue injury. Molecular Weight: 420.43 g/mol | Sequence: Non-Peptide
that was first identified in human plasma, but has First, it seems to act as a potent protector of tissue and
hence been found in multiple locations such as saliva anti-inflammatory agent that controls the oxidative DESCRIPTION:
and urine. Copper peptides are small, naturally damage that occurs post-tissue injury. Further, it then
Aminophylline and glycyrrhetinic acid transdermal cream is 18β-glycyrrhetinic acid increases the level of glycerol release
occurring protein fragments that have high affinity for plays a big role in signaling tissue remodeling which used for fat loss. Aminophylline and glycyrrhetinic prevent and up-regulates the mRNA of hormone-sensitive lipase,
copper ions, which are critical to normal body removes damaged/scarred tissue and generates new, cAMP breakdown. Cyclic AMP (cAMP) functions in adipose triglyceride lipase, and perilipin, as well as the
function. GHK-Cu has a variety of roles in the healthy tissue. However, these positive effects decline several biochemical processes including the regulation of phosphorylation of hormone-sensitive lipase. 18 β-
human body including, but not limited to, promoting with age because the concentration of GHK-Cu in glycogen, sugar, and lipid metabolism. cAMP works by glycyrrhetinic acid alters fat mass by directly affecting
TAILOR MADE COMPOUNDING

activation of wound healing, attracting immune cells, the body decreases with age. Thus, there is an increase activating protein kinase A (PKA) which assists in glycogen, adipogenesis in maturing preadipocytes and lipolysis in
antioxidant and anti-inflammatory effects, stimulating in inflammation, cancerous activity, and tissue sugar, and lipid metabolism. Aminophylline has displayed mature adipocytes. Therefore, aminophylline and 18β-
collagen and glycosaminoglycan synthesis in skin destruction. Clinically, it is mostly used to decrease topical fat reduction from the waist. In a study examining glycyrrhetinic acid may be useful for treating obesity. Both
fibroblasts, and promoting blood vessel growth. There fine lines and wrinkles and to improve hair regrowth. aminophylline cream application, the reduction in waist aminophylline and glycyrrhetinic acid combined effectively
circumference was significant for both men and women. combat fat loss. Aminophylline and glycyrrhetinic acid fat
has been evidence that has shown that it acts as a
Over a period of 12 weeks, participants in the study lost loss cream yields the best results through topical
11cm in waist circumference. In differentiated adipocytes, application.
PROTOCOL:
Content & Potency: • Injectable: 10mg/ml subcutaneous injection provided in a 5ml vial. PROTOCOL:
• Topical: 5mg/ml (5%) topical foam provided in a 50ml foaming applicator. Content & Potency: Aminophylline/Glycyrrhetinic Acid 0.5%/2.5% transdermal cream provided in
Suggested dosage: • Injectable: Inject 0.2ml subcutaneously once daily. a 60ml Topiclick cream applicator.
• Topical: Apply 1ml (2 pumps) to scalp once daily at night. Suggested dosage: Apply 1ml twice daily transdermally.

CLINICAL RESEARCH: CLINICAL RESEARCH:

18β-Glycyrrhetinic acid inhibits adipogenic differentiation and stimulates lipolysis
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
18β-Glycyrrhetinic acid (18β-GA) obtained from the herb blotting. 18β-GA dose-dependently (1–40 lM)
GHK (glycyl-L-histidyl-L-lysine) is present in human of dogs. It also induces systemic wound healing in rats,
liquorice has various pharmacological properties including significantly decreased lipid accumulation in maturing
plasma, saliva, and urine but declines with age. It is mice, and pigs. In cosmetic products, it has been found to
anti-inflammatory and anti-bacterial activities. However, preadipocytes. In 3T3-L1 preadipocytes, 10 lM of 18β-GA
proposed that GHK functions as a complex with copper 2+ tighten loose skin and improve elasticity, skin density, and
potential biological anti-obesity activities are unclear. In down-regulated the transcriptional levels of peroxisome
which accelerates wound healing and skin repair. GHK firmness, reduce fine lines and wrinkles, reduce
this study, novel biological activities of 18β-GA in the proliferator-activated receptor c, CCAAT/enhancer-binding
stimulates both synthesis and breakdown of collagen and photodamage, and hyperpigmentation, and increase
adipogenesis of 3T3-L1 preadipocytes and in lipolysis of protein and adiponectin, which are markers of adipogenic
glycosaminoglycans and modulates the activity of both keratinocyte proliferation. GHK has been proposed as a
differentiated adipocytes were identified. Mouse 3T3-L1 differentiation via Akt phosphorylation. Also, in
metalloproteinases and their inhibitors. It stimulates therapeutic agent for skin inflammation, chronic
cells were used as an in vitro model of adipogenesis and differentiated adipocytes, 18β-GA increased the level
collagen, dermatan sulfate, chondroitin sulfate, and the obstructive pulmonary disease, and metastatic colon cancer.
lipolysis, using a mixture of insulin/dexamethsone/3- of glycerol release and up-regulated the mRNA of hor-
small proteoglycan, decorin. It also restores replicative It is capable of up and down regulating at least 4,000
isobutyl-1-methylxanthine (IBMX) to induce mone-sensitive lipase, adipose TG lipase and perilipin, as
vitality to fibroblasts after radiation therapy. The molecule human genes, essentially resetting DNA to a healthier state
differentiation. The amount of lipid droplet accumulation well as the phosphorylation of hormone-sensitive lipase at
attracts immune and endothelial cells to the site of an The present review revisits GHK’s role in skin regeneration
was determined by an AdipoRed assay. The expression of Serine 563. The results indicate that 18β-GA alters fat mass
injury. It accelerates wound-healing of the skin, hair in the light of recent discoveries.
several adipogenic transcription factors and enzymes was by directly affecting adipogenesis in maturing preadipocytes
follicles, gastrointestinal tract, boney tissue, and foot pads
investigated using real-time reverse transcriptase- and lipolysis in matured adipocytes. Thus, 18β-GA may be
polymerase chain reaction (RT-PCR) and Western useful for the treatment of obesity.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

Pickart, Loren & Vasquez-Soltero, Jessica & Margolina, Anna. (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Moon, Myung-Hee et al. “18β-Glycyrrhetinic acid inhibits adipogenic differentiation and stimulates lipolysis.” Biochemical and biophysical research
Regeneration. BioMed Research International. communications 420 4 (2012): 805-10 .

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

24 25
 IGF-1 Ipamorelin
Purity: >98% (HPLC on request) | Molecular Formula: C71H119N17O19S
Molecular Weight: 1546.893 g/mol | Sequence: Gly-Pro-Glu-Thr-Leu-Cys-Gly-Ala-Glu-Leu-Val-
Asp-Ala-Leu-Gln-Phe-Val-Cys-Gly-Asp-Arg-Gly-Phe-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-
Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr-Gly-Ile-Val-Asp-Glu-Cys-Cys-Phe-Arg-Ser-Cys-Asp-Leu-Arg- Purity: >98% (HPLC on request) | Molecular Formula: C38H49N9O5
Arg-Leu-Glu-Met-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala Molecular Weight: 711.863 | Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH

DESCRIPTION: DESCRIPTION:
IGF-1 is a peptide consisting of 70 amino acids with a including muscle, bone, and cartilage tissue. IGF-1 plays an Ipamorelin is a selective GH-Secretagogue and doesn’t release the same volumes of cortisol,
molecular weight of 7649 Da. IGF-1 has an A and B chain important role in childhood growth and continues to have ghrelin receptor agonist. The potency of ghrelin acetylcholine, prolactin and aldosterone. It is
connected by disulphide bonds, like insulin, which is how anabolic effects in adults. A synthetic analog of IGF-1, stimulation can be compared to GHRP6 with for this reason Ipamorelin has been considered
it gets its name. The structural similarity to insulin explains mecasermin is commercially available and is used for the less appetite stimulation properties. However, the first selective, and best, GH Secretagogue.
the ability of IGF-1 to bind (with low affinity) to the treatment of growth failure. Therapeutic administration
insulin receptor. IGF-1 is secreted by many tissues and the of IGF-1 is associated with reversing insulin sensitivity,
unlike other GH-Secretagogues this pentapeptide

TAILOR MADE COMPOUNDING

secretory site seems to determine its actions. Most IGF-1 reducing weight and increasing metabolic expenditure as
is secreted by the liver and is transported to other tissues,
acting as an endocrine hormone. IGF-1 is also secreted by
well potential reversal of degeneration of spinalcord motor
neuron axons in certain peripheral neuropathies.
PROTOCOL:
other tissues, including cartilaginous cells, and acts locally IGF-1 LR3 has a modified amino acid sequence compared Content & Potency: 2000mcg/ml subcutaneous injectable provided in a 5ml vial.
as a paracrine hormone. to biological IGF-1. It has an additionally arginine at Suggested dosage: Inject 0.10ml subcutaneously once daily 5 out of 7 days of the week.
Most of the IGF-1 produced by the liver is secreted for its amino acid position 2. By making this change, it gives the
proliferative and growth effects. Lower IGF-1 and growth molecule higher potency and a much longer half-life. For
***We suggest using the Ipamorelin in combination with CJC 1295 as it provides a synergistic effect,
hormone are often associated with excess body fat. IGF-1 this reason it is commonly used as long acting version for
and other proteins in the IGF family are growth factors that the same therapeutic reasons as the IGF-1. generating five times the benefits of using the CJC 1295 or Ipamorelin alone. The combination
stimulate the proliferation and survival of various cell types allows for maximized release of GH because the CJC 1295 and Ipamorelin have different
mechanisms of action and work on different receptors (GHRH-R & Ghrelin-R).
PROTOCOL:
Content & Potency: 620mcg/ml subcutaneous injectable provided in two 6.2ml vials. CLINICAL RESEARCH:
Suggested dosage: Inject 0.4ml subcutaneously once daily. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human
Volunteers
CLINICAL RESEARCH: To examine the pharmacokinetics (PK) and decline to negligible GH concentration at all doses. The
pharmacodynamics (PD) of ipamorelin, a growth hormone ipamorelin-GH concentration relationship was
Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese (GH) releasing peptide, in healthy volunteers. A trial was characterized using an indirect response model and
postmenopausal women. conducted with a dose escalation design comprising 5 population fitting. The model employed a zero-order GH
To determine the effects of GH and insulin-like growth intolerable side-effects (e.g. edema). Weight loss occurred different infusion rates (4.21, 14.02, 42.13, 84.27 and release rate over a finite duration of time to describe the
factor I (IGF-I) administration, diet, and exercise on weight in all groups, with the largest decrease occurring in the GH 140.45 nmol/kg over 15 minutes) with eight healthy male episodic release of GH. Ipamorelin induces the release
loss, body composition, basal metabolic rate (BMR), plus IGF-I group (5.6 +/- 1.4 kg). Fat mass significantly subjects at each dose level. Concentrations of ipamorelin of GH at all dose levels with the concentration (SC50)
muscle strength, and psychological status, 33 moderately decreased in all groups, with the largest losses observed in and growth hormone were measured. The PK parameters required for half-maximal GH stimulation of 214 nmol/
obese postmenopausal women (67.1 +/- 5.2 yr) GH and GH plus IGF-I groups (6.3 +/- 1.8 and 8.4 +/- 2.8 showed dose-proportionality, with a short terminal half-life L and a maximal GH production rate of 694 mIU/L/h.
participated in a 12-week randomized, double blind study. kg, respectively). Despite weight loss, BMR was maintained of 2 hours, a clearance of 0.078 L/h/kg and a volume of The inter-individual variability of the PD parameters was
Participants were placed on a diet that provided 500 Cal/ in all groups. Muscle strength increased with training for all distribution at steady-state of 0.22 L/kg. The time course larger than that of the PK parameters. The proposed PK/
day less than that needed for weight maintenance, and they groups, and depression and anxiety scores decreased in of GH stimulation by ipamorelin showed a single episode PD model provides a useful characterization of ipamorelin
walked 3 days and strength trained 2 days each week. groups receiving IGF-I. These data show that obese of GH release with a peak at 0.67 hours and an exponential disposition and GH responses across a range of doses.
Subjects also self-injected GH (0.025 mg/kg BW.day), postmenopausal women can lose weight and fat without
IGF-I (0.015 mg/kg BW.day), a combination of these doses compromising fat free mass, BMR, or gains in muscle Gobburu, Jogarao & Agersø, Henrik & J. Jusko, William & Ynddal, Lars. (1999). Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a
of GH and IGF-I, or placebo (P). Twenty-eight women strength, and that GH and IGF-I given together may Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical research. 16. 1412-6.
completed the study, as ve subjects dropped out due to enhance fat loss over either given alone.
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
L Thompson, J & E Butterfield, G & K Gylfadottir, U & Yesavage, J & Marcus, Robert & L Hintz, R & Pearman, Ann & Hoffman, AR. (1998).
Effects of Human Growth Hormone, Insulin-Like Growth Factor I, and Diet and Exercise on Body Composition of Obese Postmenopausal Women 1.
The Journal of clinical endocrinology and metabolism. 83.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
26 27
 iRGD Kisspeptin-10
Purity: >98% (HPLC on request) | Molecular Formula: C35H58N14O13S2
Molecular Weight: 947.07g/mol | Sequence: Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys Purity: >98% (HPLC on request) | Molecular Formula:C63H83N17O14
Molecular Weight: 1302.462 g/mol | Sequence:Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH
DESCRIPTION:
iRGD is a cyclic peptide that binds to integrins better and makes the therapy less toxic. One DESCRIPTION:
that are expressed on tumor endothelial cells. study showed that doxorubicin, liposomal Kisspeptins are a group of neuroendocrine Leydig cells to produce testosterone without the
Upon binding, a protease cleavage event is doxorubicin, Herceptin trastuzumab or Abraxane peptides that stimulate the release of result of hypogonadism shown with exogenous
activated. When this event is activated the nab-paclitaxel had greater drug accumulation in Gonadotropin Releasing Hormone (GnRH) and testosterone usage. The expression of Kiss1 has
peptide is then able to bind neuropilin-1, the tumor by up to 40-fold than mice injected is involved in the regulation of developmental also been altered in other situations of energy
activating an endocytotic/exocytotic transport with one of the drugs alone. They equaled greater sex hormones at the beginning stages of puberty. imbalance such as obesity and diabetes. It has also
pathway. As a result of this, it is able to hone to reductions in tumor growth. In all, the drug- There have been problems in maturation centered been shown to reverse the effects of
TAILOR MADE COMPOUNDING

tumor cells and make them permeable to peptide combination was as effective as threefold around receptor mutations for kisspeptin. hypogonadotropic hypogonadism. It also shows
transport of many types of cancer therapies. This higher doses of drug alone. Kisspeptins are encoded by the KISS1 gene, other physiologic effects such as helping with egg
makes traditional cancer therapies target cells which was originally identified as a human implantation and maturation in reproduction, as
metastasis suppressor gene for melanoma and well as the prevention of ectopic pregnancy.
PROTOCOL: breast cancer. Kisspeptins have shown therapeutic Further, in the kidneys it has been shown to
Content & Potency: 2.5mg/ml subcutaneous injection provided in a 10ml vial. benefits regarding the upregulation of the increase aldosterone production as well as
Suggested dosage: 40mcg/kg subcutaneously once daily in combination with other Cancer endogenous production of Luteinizing Hormone pregnenolone breakdown and kisspeptin –
treatment. (LH) and Follicular Stimulating Hormone (FSH) angiotensin2 production.
through the HPA axis. Thus, it can stimulate

CLINICAL RESEARCH: PROTOCOL:

Co-administration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Content & Potency: 100mcg/ml subcutaneous injection provided in a 5ml vial.
Poor penetration of anti-cancer drugs into tumors can be injection with iRGD improved the therapeutic index of
Suggested dosage: Inject 0.10ml subcutaneously once daily.
an important factor limiting their efficacy. Studying mouse drugs of various compositions including a small molecule
tumor models, we show that a previously characterized (doxorubicin), nanoparticles (nab-paclitaxel and
tumor-penetrating peptide, iRGD (CRGDK/RGPD/EC), doxorubicin liposomes), and a monoclonal antibody CLINICAL RESEARCH:
increased vascular and tissue permeability in a tumor- (trastuzumab). Thus, co-administration of iRGD may be
specific and neuropilin-1-dependent manner, allowing a valuable way to enhance the efficacy of anti-cancer drugs Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men
co-administered drugs to penetrate into extravascular while reducing their side effects, a primary goal of cancer Intravenous bolus kisspeptin-10 resulted in a rapid and secretion, but a lower dose infusion of kisspeptin-10 (1.5
tumor tissue. Importantly, this effect did not require the therapy research. dose-dependent rise in serum LH concentration, with μg/kg · h) increased mean LH from 5.2 ± 0.8 to 14.1 ± 1.7
drugs to be chemically conjugated to the peptide. Systemic maximal stimulation at 1 μg/kg (4.1 ± 0.4 to 12.4 IU/liter (n = 4; P < 0.01) and increased LH pulse frequency
± 1.7 IU/liter at 30 min, P < 0.001, n = 6). Administration from 0.7 ± 0.1 to 1.0 ± 0.2 pulses/h (P < 0.05) and secre-
Sugahara, Kazuki N et al. “Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.” Science (New York, N.Y.) vol. of 3 μg/kg elicited a reduced response vs. 1 μg/kg (P < tory burst mass from 3.9 ± 0.4 to 12.8 ± 2.6 IU/liter (P <
328,5981 (2010) 0.05). Infusion of kisspeptin-10 at 4 μg/kg · h for 22.5 h 0.05). Kisspeptin-10 boluses potently evoke LH secretion
elicited an increase in LH from a mean of 5.4 ± 0.7 to 20.8 in men, and continuous infusion increases testosterone, LH
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
± 4.9 IU/liter (n = 4; P < 0.05) and serum testosterone pulse frequency, and pulse size. Kisspeptin analogues have
increased from 16.6 ± 2.4 to 24.0 ± 2.5 nmol/liter (P < therapeutic potential as regulators of LH and thus
0.001). LH pulses were obscured at this high rate of testosterone secretion.

George, J T et al. “Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.” The Journal of clinical endocrinology and
metabolism vol. 96,8 (2011): E1228-36. doi:10.1210/jc.2011-0089

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

28 29
 KPV
Purity: >99% (confirmed by HPLC) | Molecular Formula: Ac-C16H32N4O6-NH2
Leuphasyl
Molecular Weight: 378.47 g/mol | Sequence: Lys-Pro-Val
Purity: >99% (HPLC on request) | Molecular Formula: C29H39N5O7
DESCRIPTION: Molecular Weight: 569.659 g/mol | Sequence: Tyr-D-Ala-Gly-Phe-Leu

KPV (Lysine-Proline-Valine) is a C-terminal

tripeptide fragment of α-melanocyte stimulating
anti-inflammatory properties especially in those with
psoriasis. Psoriasis is a chronic autoimmune condition
DESCRIPTION:
hormone (α-MSH). α-MSH stimulates the which causes the rapid build-up of skin cells and is Leuphasyl, pentapeptide-18, is a five amino acid It is important to note that leuphasyl and
production and release of melanin by melanocytes usually treated using hydrocortisone. In people with peptide that reduces the depth of wrinkles by argireline have a synergistic effect. For 28 days,
in skin and hair, acting through melanocortin 1 psoriasis, KPV has shown to limit symptoms of the contraction of facial muscles. It is an enkephalin a cream containing 5% argireline solution and a
receptor. Several studies have previously shown that condition including itchiness, dryness, redness, modified for enhanced stability that modulates 5% leuphasyl solution was applied twice daily to
KPV has decreased inflammation and tumorigenesis peeling, and more. Therefore, KPV could be used acetylcholine activity in neuron cells and the eyes of 43 volunteers. 24.62% wrinkle
in the body. The KPV anti-inflammatory effect is for an extended period of time without risking the
catecholamine release. Leuphasyl targets the reduction was observed in the participants using

TAILOR MADE COMPOUNDING

PepT1-mediated in intestinal epithelial and immune unwanted complications of long term steroid
cells. PepT1 is an oligopeptide transporter that is therapy. KPV is a promising, therapeutic treatment
wrinkle-formation mechanism of the expression the solution. Due to their complementary
overexpressed in the in the colonic epithelial cells of for inflammatory bowel disease (IBD), colon of wrinkles in a unique way, offering an mechanisms, both peptides show additive effects.
chronic ulcerative colitis, which can deliver KPV into cancer, and inflammatory skin disorders, in particular, alternative to other cosmetic peptides like Leuphasyl indicates a proven efficacy for
cytosol in the intestine. psoriasis. argireline and SNAP-8. improving firmness and skin tone, reducing fine
The tripeptide, KPV has significant antimicrobial and lines and wrinkles, and moisturizing the skin.

PROTOCOL: PROTOCOL:
Content & Potency: 30ml TopiClick at 15mg/ml Content & Potency: 5%/5% cream (with Argireline) in 30ml TopiClick
Suggested dosage: 0.5ml applied to area twice daily Suggested dosage: 1ml applied topically to the face daily

CLINICAL RESEARCH: CLINICAL RESEARCH:

Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Anti Inflammatory and Protective The Efficiency and Safety of Leuphasyl—A Botox-Like Peptide
Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases
Peptides of synthesis are a very new strategy in cosmetic muscle and a reduction of expression wrinkles. The aim
Alpha-MSH is a tridecapeptide derived from been validated in animal models of experimentally induced science and technology for at least two reasons: (1) they are of our study is to evaluate the optimal concentration of
proopiomelanocortin. Many studies over the last few years fever; irritant and allergic contact dermatitis, vasculitis, and small molecules, easily penetrable in the skin and (2) they Leuphasyl for skin application at the mimic muscle level,
have provided evidence That Alpha -MSH has potent fibrosis; ocular, gastrointestinal, brain, and allergic airway are able to induce a very specific action, because all skin the efficiency and the safety of this peptide. We formulated
protective and antiinflammatory effects. These effects can inflammation; and arthritis, but also in models of organ cells (keratinocytes, fibroblasts, nervous cells) have three emulsions of different concentrations (0.5%, 1%,
be elicited via centrally expressed melanocortin receptors injury. One obstacle limiting the use of alpha-MSH in membrane receptors for peptides. This group of 2%) which were applied to the skin, at the level of mimic
that orchestrate descending neuro-genic antiinflammatory inflammatory disorders is its pigmentary effect. Due to its cosmeceutics includes the botox-like peptides, represented muscles (1) at the eyebrows zone (above the corrugator
pathways. Alpha-MSH can also exert antiinflammatory and preserved antiinflammatory effect but lack of pigmentary by acetyl hexapeptide 3 (Argireline) and pentapeptid-3 supercilii muscle) and (2) at the periorbital zone (above the
protective effects on cells of the immune system and on action, the C-terminal tripeptide of -MSH, KPV, has been (Leuphasyl). The latter is less known and has been less orbicularis oculi muscle). We evaluated the regression of the
peripheral nonimmune cell types expressing melanocortin delineated as an alternative for antiinflammatory therapy. studied. This substance inhibits the neuromuscular synapses wrinkles between the eyebrows using an imagistic method:
receptors. At the molecular level, Alpha-MSH affects KdPT, a derivative of KPV corresponding to amino acids in the mimic muscles, acting as enkephalins. It links the pro-derm Analyser. The study is of interest to discussions
various pathways implicated in regulation of inflammation 193–195 of IL-1, is also emerging as a tripeptide with enkephalin receptor to nervous cells, thereby modulating concerning how to apply these kinds of cosmetic products
and protection, i.e., nuclear factor-B activation, expression antiinflammatory effects. The physicochemical properties the release of acetylcholine in synaptic space. This cellular at the mimic muscle skin level and not at the level of the
of adhesion molecules and chemokine receptors, produc- and expected low costs of production render both agents activity will be translated in vivo in a relaxation of the wrinkles.
tion of proinflammatory cytokines and mediators, IL-10 suitable for the future treatment of immune-mediated
synthesis, T cell proliferation and activity, inflammatory inflammatory skin and bowel disease, fibrosis, allergic
Anca O. Dragomirescu, Mihaiela Andoni *, Daniela Ionescu and Felicia Andrei Department II, Faculty of Pharmacy, University of Medicine and Phar-
cell migration, expression of antioxidative enzymes, and and inflammatory lung disease, ocular inflammation, and
macy “Victor Babeş”, Timişoara, Square E. Murgu No. 2, Timişoara 300041, Romania;
apoptosis. The antiinflammatory effects of -MSH have arthritis.
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
Endocr Rev. 2008 Aug;29(5):581-602. doi: 10.1210/er.2007-0027. Epub 2008 Jul 8. Brzoska T1, Luger TA, Maaser C, Abels C, Böhm M.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
30 31
 LL-37 Melanotan II
Purity: >98% (HPLC on request) | Molecular Formula: C205H340N60O53
Molecular Weight: 4493.33 g/mol | Sequence: Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu- Purity: >98% (HPLC on request) | Molecular Formula: C50H69N15O9
Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg- Molecular Weight: 1024.2 | Sequence: Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2(cyclic 2-7)
Thr-Glu-Ser
DESCRIPTION:
DESCRIPTION: Melanotan I and Melanotan II are both analogs hormone melanin. Scientists have also noticed
LL-37 Is an antimicrobial peptide which belongs through the skin. LL-37 plays an important role of the peptide hormone alpha-melanocyte- that MT 2 had a positive effect on libido due
to the cathelicidin family of AMPs(antimicrobial in the first line of defense against infection and stimulating hormone (α-MSH) that induces skin to its aphrodisiac properties. Additionally, MT
peptides). LL-37, like cathelicidins, are stored systemic invasion of pathogens at sites of tanning. Like its predecessor, Melanotan I, MT 2 exhibits a mild positive fat-mobilizing effect.
in neutrophil granules as inactive precursors and inflammation and wound. It is cytotoxic to both 2 plays a role in stimulating melanogenesis and Melanotan I is an FDA approved drug under the
are released as mature peptides when neutrophils bacterial and normal eukaryotic cells and is thus provides a protective mechanism against UV brand name Scenesse. Scenesse is most
TAILOR MADE COMPOUNDING

are stimulated. LL-37 is expressed in various cells significantly resistant to proteolytic degradation rays since under its actions melanocytes are able commonly used to treat patients that have an
and tissues such as circulating neutrophils and in solution. LL-37 shows a broad spectrum of to increase production and secretion of the intolerance to light.
myeloid bone marrow cells, epithelial cells of the antimicrobial activity against bacteria,
skin, and is also expressed in the gastrointestinal
tract, as well as in the epididymis and lungs.
enveloped viruses, and fungi. It has also
demonstrated success in helping promote wound
PROTOCOL:
Moreover, production of LL-37 in macrophages healing but it may play a negative role in atopic Content & Potency: 2000mcg/ml subcutaneous injection provided in a 5ml vial.
is stimulated by vitamin D released by sunlight dermatitis and psoriasis. Suggested dosage: Inject 0.15ml once daily for 1 - 2 weeks then 0.25mL twice weekly thereafter for
maintenance.
PROTOCOL: For CIRS: Inject 100mcg every other day for 40 days.

Content & Potency: 2000mcg/ml subcutaneous injection provided in a 5ml vial.

Suggested dosage: Varies with indication and patient. CLINICAL RESEARCH:
Evaluation of melanotan-II, a super potent cyclic melanotropic peptide in a pilot phase-I clinical study.

CLINICAL RESEARCH: A pilot phase I study was conducted with a cyclic

heptapeptide analog of alpha-melanocyte stimulating
II somnolence and fatigue in one of two subjects (WHO
standards). Mild nausea, not requiring antiemetic
Membrane Core-Specific Antimicrobial Action of Cathelicidin LL-37 Peptide Switches Between Pore and Nanofi- hormone (alpha-MSH). The lactam-bridged molecule, treatment, was reported at most MT-II dose levels. A
bre Formation called Melanotan-II (MT-II), has the structure stretching and yawning complex appeared to correlate with
Membrane-disrupting antimicrobial peptides provide the membrane forming lipids. We demonstrate that LL-37 Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha- the onset of spontaneous, Penile erections which were
broad-spectrum defence against localized bacterial invasion exhibits two distinct interaction pathways: pore formation MSH4-10-NH2 (MT-II) and has superpotent intermittently experienced for 1-5 hours after MT-II
in a range of hosts including humans. The most generally in bilayers of unsaturated phospholipids and membrane melanotropic activity in vitro. A single-blind, alternating dosing, depending on the MT-II dose. Two subjects had
held consensus is that targeting to pathogens is based on modulation with saturated phospholipids. Uniquely, the day (saline or MT-II), placebo-controlled trial was increased pigmentation in the face, upper body and
interactions with the head groups of membrane lipids. Here membrane modulation yields helical-rich fibrous conducted in 3 normal male volunteers at the buttock, as measured by quantitative reflectance and by
we show that the action of LL-37, a human peptide-lipid superstructures. Our results point at starting dose of 0.01 mg/kg of MT-II. Subcutaneous visual perception 1 week after MT-II dosing ended. These
antimicrobial peptide switches the mode of action based on alternative design strategies for peptide antimicrobials. injections of MT-II or saline were given daily (Monday- results demonstrate that MT-II has tanning activity in
the structure of the alkyl chains, and not the head groups of Friday) for 2 consecutive weeks. Two subjects were humans given only 5 low dose every other day by
escalated by 0.005 mg/kg increments to 0.03 mg/kg and subcutaneous injection. The recommended single MTII
one to 0.025 mg/kg. The 0.03 mg/kg dose produced Grade dose for future Phase I studies is 0.025 mg/kg/day.
Shahmiri, Mahdi & Enciso, Marta & Adda, Christopher & Smith, Brian & Perugini, Matthew & Mechler, Adam. (2016). Membrane Core-Specific
Antimicrobial Action of Cathelicidin LL-37 Peptide Switches Between Pore and Nanofibre Formation. Scientific Reports.
T. Dorr, Robert & Lines, Ruskin & Levine, Norman & Brooks, Chris & Xiang, Li & Hruby, Victor & E. Hadley, Mac. (1996). Evaluation of
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life sciences. 58. 1777-84.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

32 33
 Met-Enkephalin MOTS-c
Purity: >95% (confirmed by HPLC) | Molecular Formula: C27H35N5O7S Purity: >98% (HPLC on request) | Molecular Formula: C101H152N28O22S2. C2HF3O2.
Molecular Weight: 573.66 g/mol | Sequence: H-Tyr-Gly-Gly-Phe-Met-OH Molecular Weight: 2288.6 g/mol | Sequence: MRWQEMGYIFYPRKLR

DESCRIPTION: DESCRIPTION:
In 1975, Met-Enkephalin (ME) was first isolated from receptor that is distinct from the neural opioid receptors. Human mitochondrial DNA (mtDNA) encodes 37 of energy metabolism), and AICAR (5-
porcine brain matter. ME is an endogenous pentapeptide OGF activates a specific receptor called the opioid growth known genes, including 2rRNAs, 22 tRNAs and 13 Aminoimidazole-4-carboxamide ribonucleotide)
with antagonist activity at the μ and δ opioid receptors. factor receptor (OGFr or ζ-opioid receptor). The OGF and polypeptide subunits of the electron transport chain accumulation which activates AMPK (5’- adenosine
It is one of two forms of enkephalin, the other form being OGFr axis regulates cell growth in normal and abnormal (ETC) complexes. Recent work has revealed that the monophosphate-activated protein kinase). This acts as
leu-enkephalin. Essentially, this peptide functions as a cells. It has been concluded that ME could potentially be rRNA loci contain small open reading frames (ORFs) an energy sensor by monitoring the ratio of AMP and
neurotransmitter or neuromodulator in the central nervous used as a drug to treat cancer and work as a strong immune that can be transcribed and translated into short ATP. AMPK restores homeostasis by initiating
system (CNS). Opioid receptors play a role in numerous booster. Modulation of the OFG-OGFr receptor axis peptides called mitochondrial-derived peptides catabolic processes for ATP production in case of
physiological processes in the body including pain represents a promising and therapeutic avenue for effective (MDPs), which have biological activity. MOTS-c is a energy deficits. In addition, literature suggest that

TAILOR MADE COMPOUNDING

mediation, opiate dependence, and euphoria. ME acts as treatment such as cancer (hepatoblastoma, breast, colon,
mitochondrial-encoded peptide with 16-aa’s encoded MOTS-c decreases insulin resistance and increases
a cytokine, a small secreted protein released by cells which renal, ovarian, pancreatic, melanoma and many others),
have a specific effect on the interactions and autoimmune encephalomyelitis, and multiple sclerosis.
within the 12S rRNA locus of mtDNA in human GLUT4 uptake in muscle.
communications between cells, and has demonstrated to Low-dose naltrexone (LDN) actually functions by cells. The peptide is mainly used for weight loss (regulating
increase immune functions at low concentration while increasing endogenous levels of enkephalins. As a result, MOTS-c can translocate into the nucleus in response muscle and fat metabolism) and energy (cell survival
suppressing at high concentration. In addition, ME behaves it is postulated that Met-enkephalin can also be used as an to metabolic stress and regulation of adaptive nuclear in toxic conditions). MOTS-c is consistently used by
as an opioid growth factor (OGF) on many cell types as a alternative to LDN. gene expression. This allows the peptide to promote sports performance athletes to enhance one’s
resistance of metabolic stress by upregulating the performance. It also displays a promising effect in
PROTOCOL: mitochondrial genome. Upregulating these genes
encourages mitochondrial biogenesis. MOTS-c
longevity. The Japanese long-lived people (population
with the longest lifespan in the world) have
Content & Potency: 10mg Lyophilized Vial inhibits the methionine-folate cycle resulting in demonstrated a phenotypic expression and biological
Suggested dosage: 10mg IV once weekly purine synthesis, increase in PCG-1α (a key regulator link between MOTS-c and an extended lifespan.

CLINICAL RESEARCH: PROTOCOL:

Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic Cancer Content & Potency:10mg/ml solution provided in a 4ml vial.
Background: Advanced pancreatic cancer carries the 250 μg/kg intravenously. Outcomes measured included Suggested dosage: Inject 10mg subcutaneously weekly into the abdomen.
poorest prognosis of all gastrointestinal malignancies. Once clinical benefit, tumor response by radiographic imaging,
the tumor has spread beyond the margins of the pancreas,
chemotherapy is the major treatment modality offered to
quality of life, and survival.
Results: Clinical benefit response was experienced by 53% CLINICAL RESEARCH:
patients; however, chemotherapy does not significantly of OGF-treated patients compared to historical controls of The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and
improve survival. 23.8% and 4.8% for gemcitabine and 5-fluorouracil Insulin Resistance
Objective: Opioid growth factor (OGF; [Met5]- 5-FU), respectively. Of the subjects surviving more than
Mitochondria are known to be functional organelles, but homeostasis. Its primary target organ appears to be the
enkephalin) is a natural peptide that has been shown to eight weeks, 62% showed either a decrease or stabilization
their role as a signaling unit is increasingly being skeletal muscle, and its cellular actions inhibit the folate
inhibit the growth of pancreatic cancer in cell culture and in tumor size by computed tomography. The median
appreciated. The identification of a short open reading cycle and its tethered de novo purine biosynthesis, leading
in nude mice. The purpose of this study was to evaluate survival time for OGF-treated patients was three times that
frame (sORF) in the mitochondrial DNA (mtDNA) that to AMPK activation. MOTS-c treatment in mice prevented
the effects of OGF biotherapy on subjects with advanced of untreated patients (65.5 versus 21 days, p 0.001). No
encodes a signaling peptide, humanin, suggests the possible age-dependent and high-fat-diet-induced insulin resistance,
pancreatic cancer who failed chemotherapy. adverse effects on hematologic or chemistry parameters
existence of additional sORFs in the mtDNA. Here we as well as diet-induced obesity. These results suggest that
Methods: In a prospective phase II open-labeled clinical were noted, and quality of life surveys suggested
report a sORF within the mitochondrial 12S rRNA 1mitochondria may actively regulate metabolic homeostasis
trial, 24 subjects who failed standard chemotherapy for improvement with OGF.
encoding a 16-amino-acid peptide named MOTS-c at the cellular and organismal level via peptides encoded
advanced pancreatic cancer were treated weekly with OGF
(mitochondrial open reading frame of the 12S rRNA-c) within their genome.
that regulates insulin sensitivity and metabolic
Jill P Smith, Sandra I Bingaman, David T Mauger, Harold H Harvey, Laurence M Demers, Ian S Zagon
Departments of Medicine, Public Health Sciences, Pathology, and Neurosciences and Anatomy, Pennsylvania State University, College of Medicine,
Lee, Changhan & Zeng, Jennifer & G. Drew, Brian & Sallam, Tamer & Martin-Montalvo, Alejandro & Wan, Junxiang & Kim, Su-Jeong & Mehta,
Hershey Medical Center, Hershey, PA, USA
Hemal & Hevener, Andrea & Cabo, Rafael & Cohen, Pinchas. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis
and Reduces Obesity and Insulin Resistance. Cell metabolism. 21. 443-454.
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
34 35
 MK-677 Myristyl
Purity: >98% (HPLC on request) | Molecular Formula: C27H36N4O5S Purity: >98% (HPLC on request) | Molecular Formula: CH3(CH2)12CO-hE18A-NH2
Molecular Weight: 528.668 g/mol | Sequence: Non- peptide Molecular Weight: 3805.67 g/mol | Sequence: Myr-Leu-Arg-Arg-Leu-Arg-Arg-Arg-Leu-Leu-Arg-
Asp-Trp-Leu-Lys-Ala-Phe-Tyr-Asp-Lys-Val- Ala-Glu-Lys-Leu-Lys-Glu-Ala-Phe-NH2
DESCRIPTION:
MK-677 is a long active orally bioactive agonist decrease adipose tissue. It has been shown to DESCRIPTION:
of the GHS-R1a. As such, binds to the same increase lean muscle mass and might be a good The hepatic uptake of LDL is highly regulated. The LDL (HSPG). Like apoE, Ac-hE18A-NH2 and its variants can
receptor that GHRP2, GHRP6, and Ipamorelin candidate for sarcopenic patients with low bone receptor (LDL-R) present on hepatocytes mediates the reduce plasma cholesterol and displays anti-inflammatory
endocytosis of LDL and thus regulates the plasma level of properties in model animals. Ac-hE18A-NH2 has already
also stimulate. Also called Ibutamoren, it has mineral density. In order to reduce the negative the lipoprotein and cholesterol. In the acidic environment undergone phase 1 clinical trials as a lipid-lowering agent.
shown to cause a predictable rise in IGF-1 but effect of somatostatin, MK-677 is best taken on of the endosome, the LDL-R dissociates from its ligand and In a recent study, the myristyl peptide variant of ApoE
unlike other GH secretagogues doesn’t help to an empty stomach with no insulin in the system. recycles back to the cell surface for further uptake of LDL. has been shown to reduce total and LDL cholesterol (even
TAILOR MADE COMPOUNDING

Apo E is an alternate ligand for the LDL-R and under severe dyslipidemic conditions) in apoE-null mice.

PROTOCOL: mediates the clearance of triglyceride-rich lipoproteins

such as chylomicron remnants and VLDL (2). ApoE
As a result, it is though myristyl can act as an alternative to
statins and HMG-CoA reductase inhibitors. Additionally,
Content & Potency: 25mg capsules provided in quantities of 30. also binds to additional hepatic receptors such as LDL-R because of its enhanced potency at lower doses, myristyl has
related protein (LRP) and heparan sulfate proteoglycans great therapeutic potential to lower cholesterol.
Suggested dosage: Take one capsule by mouth once daily on an empty stomach.

CLINICAL RESEARCH: PROTOCOL:

Content & Potency: 5ml vial at 6mg/ml
Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults A Suggested dosage: 100mcg/kg once weekly intravenously
Randomized Trial
Daily administration of MK-677 significantly increased
growth hormone and insulin-like growth factor I levels
mmol/L (5 mg/dL) in the MK-677 group (P 0.015), and
insulin sensitivity decreased. The most frequent side effects
CLINICAL RESEARCH:
to those of healthy young adults without serious adverse were an increase in appetite that subsided in a few months Novel Fatty Acyl ApoE Mimetic Peptides Have Increased Potency To Reduce Plasma Cholesterol In Mice
effects. Mean fat-free mass decreased in the placebo group and transient, mild lower-extremity edema and muscle And Macaques
but increased in the MK-677 group (change, 0.5 kg [95% pain. Low-density lipoprotein cholesterol levels decreased Ac-hE18A-NH2 is a dual-domain apoE mimetic peptide apoE-null mice fed standard chow or a Western diet; the
CI, 1.1 to 0.2 kg] vs. 1.1 kg [CI,0.7 to 1.5 kg], in the MK-677 group relative to baseline values (change, that possesses the putative receptor binding domain from myristyl analog was the most effective. A single
respectively; P 0.001), as did body cell mass, as reflected by 0.14 mmol/L [CI,0.27 to 0.01 mmol/L]; 5.4 mg/dL [CI, apoE (LRKLRKRLLR, denoted hE, residues 141 to 150) administration of the myristyl analog reduced plasma total
intracellular water (change, 1.0 kg [CI, 2.1 to 0.2kg] vs. 0.8 10.4 to 0.4 mg/ dL]; P 0.026); no differences between the covalently attached to lipid-associating peptide 18A. Like and LDL cholesterol in a dose-dependent manner in
kg [CI, 0.1 to 1.6 kg], respectively; P 0.021). No groups were observed in total or high-density lipoprotein apoE, Ac-hE18A-NH2 reduces plasma cholesterol in hypercholesterolemic cynomolgus macaques for up to 1
significant differences were observed in abdominal visceral cholesterol levels. Cortisol levels increased 47 nmol/L (CI, animal models and exhibits anti-inflammatory properties week despite continuation of a cholesterol-supplemented
fat or total fat mass; however, the average increase in limb 28 to 71 nmol/L (1.7 g/dL [CI, 1.0 to 2.6 g/dL]) in MK- independent of its cholesterol-reducing effect. diet. The myristyl peptide (7.4 mg/kg) reduced total and
fat was greater in the MK-677 group than the placebo 677 recipients (P 0.020). Changes in bone mineral density Ac-hE18A-NH2 has already undergone phase I clinical LDL cholesterol at 24 hours by 64% and 74%,
group (1.1 kg vs.0.24 kg; P 0.001). Body weight increased consistent with increased bone remodeling occurred in trials as a lipid-lowering agent. To explore the therapeutic respectively; plasma HDL levels were modestly reduced and
0.8 kg (CI, 0.3 to 1.8 kg) in the placebo group and 2.7 kg MK-677 recipients. Increased fat-free mass did not result potential, we designed and synthesized new analogs by returned to baseline by the seventh day. These new analogs
(CI, 2.0 to 3.5 kg) in the MK-677 group (P 0.003). in changes in strength or function. Two-year exploratory linking ɑ-aminohexanoic acid, octanoic acid, or myristic should exhibit enhanced potency at lower doses than
Fasting blood glucose level increased an average of 0.3 analyses confirmed the 1-year results. acid to LRRLRRRLLR-18A-NH2 ([R]hE18A-NH2) and Ac-hE18A-NH2, which may make them attractive
examined the cholesterol-lowering potency in animals. The therapeutic candidates for clinical trials.
Nass, Ralf et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Annals of modified peptides effectively reduced plasma cholesterol in
internal medicine vol. 149,9 (2008): 601-11.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. Gattadahalli M. Anantharamaiaha, David W. Garbera, Dennis Goldbergb, Eric Morrelb, Geeta Dattaa, Mayakonda N. Palgunacharia, Thomas C.
Register, Susan E. Appt, and C. Roger Whitea* Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham,
Alabama 35294, LipimetiX Development, Inc. 5 Commonwealth Rd. Suite 2A, Natick, MA 01760, Wake Forest School of Medicine, Winston-Salem,
NC 27157

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

36 37
 NMN PEG-MGF
Purity: >97% (HPLC on request) | Molecular Formula: C32H42N9O22P3 Purity: >98% (HPLC on request) | Molecular Formula: C121H200N42O39
Molecular Weight: 997.65 g/mol | Sequence: Non-peptide Molecular Weight: 2888.16 | Sequence: Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-
Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys
DESCRIPTION:
Nicotinamide adenine dinucleotide (NAD+) and profile, enhanced eye function and other DESCRIPTION:
its reduced form NADH are essential cofactors pathophysiologies. It has also prevented age- MGF is a split variant of IGF-1 but its sequence required for repair and for the hypertrophy
for multiple cellular metabolic reactions and has a associated gene expression changes in key differs from the systemic IGF-1 produced by process, which may have similar regulatory
central role in energy production. Nicotinamide metabolic organs and enhanced mitochondrial the liver. IGF-I is spliced towards MGF which mechanisms. MGF is essential for repair and
mononucleotide (NMN) is a key NAD+ oxidative metabolism and mitonuclear protein initiates hypertrophy and repair of local muscle therefore growth of new cells, similar to IGF-1.
intermediate that has been shown to enhance imbalance in skeletal muscle. NAD+ with the damage. MGF is expressed by mechanically If MGF is not PEGylated, the half-life lasts only
NAD+ biosynthesis. NMN has suppressed addition of NMN enhances physical performance overloaded muscle and is involved in tissue repair minutes therefore PEGylated MGF must be

TAILOR MADE COMPOUNDING

age-associated body weight gain, enhanced energy and serves as an effective anti-aging intervention and adaptation. It is expressed as a pulse considered during the compounding process to
metabolism, promoted physical activity, in humans. following muscle damage and is involved in the ensure an appropriate half-life, thereby increasing
improved insulin sensitivity and plasma lipid activation of muscle satellite (stem) cells. These duration of action.
donate nuclei to the muscle fibers that are
PROTOCOL:
Content & Potency: 10ml vial at 200mg/ml PROTOCOL:
Suggested dosage: 200mg injected subcutaneously twice daily. Content & Potency: 2000mcg/ml subcutaneous injection provided in a 5ml vial.
Suggested dosage: Inject 0.10ml to 0.20ml once daily for 5 out of 7 days of the week.

CLINICAL RESEARCH: CLINICAL RESEARCH:

Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule Expression of IGF-1 Isoforms after Exercise-induced Muscle Damage in Humans: Characterization of the MGF E
Peptide Actions In Vitro
Nicotinamide mononucleotide (NMN) is a nucleotide pharmacological activities in preclinical studies, which
that is most recognized for its role as an intermediate of suggest its potential therapeutic use. Mostly mediated by its Different insulin-like growth factor-1 (IGF-1) isoforms, up-regulation of MGF mRNA expression which was
nicotinamide adenine dinucleotide (NAD+) biosynthesis. involvement in NAD+ biosynthesis, the pharmacological namely IGF-1Eb and IGF-1Ec (MGF),have been proposed followed by a prolonged increase of IGF-1Ea and IGF-1Eb
Although the biosynthetic pathway of NMN varies activities of NMN include its role in cellular biochemical to have various functions in muscle repair and growth. To mRNA expression (p<0.05). Patterns similar to those for
between eukaryote and prokaryote, two pathways are functions, cardioprotection, diabetes, Alzheimer’s disease, gain insight into the potentially differential actions of IGF- mRNA expression were detected for MGF and IGF-1Ea
mainly followed in case of eukaryotic human—one is and complications associated with obesity. The recent 1 isoforms in the regulation of muscle regeneration, we expression at the protein level. The action of synthetic
through the salvage pathway using nicotinamide while the groundbreaking discovery of anti- ageing activities of assessed the time course of their expressions at both mRNA MGF E peptide differed from that of mature IGF1 since its
other follows phosphorylation of nicotinamide riboside. this chemical moiety has added a valuable essence in the and protein levels after exercise-induced muscle damage in proliferative effect on C2C12 myoblast-like cells was not
Due to the unavailability of a suitable transporter, NMN research involving this molecule. This review focuses on humans. In addition, we characterized mature IGF-1 and blocked by an anti-IGF-1 receptor neutralizing antibody
enters inside the mammalian cell in the form of the biosynthesis of NMN in mammalian and prokaryotic synthetic MGF E peptide signalling in C2C12 and it did not phosphorylate Akt. Therefore, we conclude
nicotinamide riboside followed by its subsequent cells and mechanism of, absorption along with the reported myoblast- like cells in vitro. Ten healthy male volunteers that the differential expression profile of IGF-1 isoforms in
conversion to NMN and NAD+. This particular pharmacological activities in murine model. were subjected to exercise-induced muscle damage and vivo and the possible IGF-1R- independent MGF E
molecule has demonstrated several beneficial biopsy samples were taken from the exercised muscles peptide signalling in skeletal muscle-like cells in vitro
before and 6 h, 2,5 and 16 days post exercise. Muscle support the notion that tissue-specific mRNA expression
Saikat Kumar Poddar,1,* Ali Ehsan Sifat,1 Sanjana Haque,1 Noor Ahmed Nahid,1 Sabiha Chowdhury,1 and Imtias Mehedi2 damage was documented by specific functional and of MGF isoform produces mature IGF-1 and MGF E
biochemical responses post exercise. PCR-based analyses peptides which possibly act as distinct mitogens in skeletal
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. of muscle biopsy samples revealed a rapid and transient muscle regeneration.

Philippou, Anastassios & Papageorgiou, E & Bogdanis, Gregory & Halapas, Antonios & Sourla, A & Maridaki, Maria & Pissimissis, Nikolas &
Koutsilieris, Michael. (2009). Expression of IGF-1 Isoforms after Exercise-induced Muscle Damage in Humans: Characterization of the MGF E Peptide
Actions In Vitro. In vivo (Athens, Greece). 23. 567-75.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

38 39
 Pentosan Polysulfate PNC-27
Purity: >98% (HPLC on request) | Molecular Formula: C188H293N53O44S
Purity: >98% (HPLC on request) | Molecular Formula: (C5H6Na2O10S2)n
Molecular Weight: 4031.7 g/mol | Sequence: PPLSQETFSDLWKLL
Molecular Weight: 602.473 g/mol | Sequence: Non- peptide

DESCRIPTION: DESCRIPTION:
PNC-27 is a membrane active anticancer peptide be selectively targeted for necrosis and death.
Pentosan polysulfate is a semi-synthetic that may help clear the subchondral circulation.
that has been found to kill cancer cells by This complex works in cancer cell membranes.
polysulfated xylan used for the relief of In one study, after a series of four to six
inducing membranoylsis via cellular Together, PNC-27 and Mdm2 result in
Osteoartritis. The mechanism of PPS action in intra- articular PPS injections into knees of
necrosis. It has been designed to bind tightly to trans-membrane pore formation which results
osteoarthritis is multifactorial, with both human volunteers, there was a significant
the p53-binding pocket on the mdm2 protein, a in cancer cell death. This is evident in literature
stimulation of cartilage matrix synthesis and increase in the size of the synovial fluid
negative regulator of the P53 tumor suppressor. including studies on P53-null K562 in leukemia
prevention of cartilage breakdown. There are also hyaluronan without causing any inflammation or
TAILOR MADE COMPOUNDING

Almost all cancers have a mechanism to decrease cells, melanoma, pancreatic cancer, breast cancer,
systemic effects on blood lipid and fibrinolysis bleeding into the joint cavity.
the functionality of P53 which can stop cellular epithelial ovarian cancer, and additional cancers.
replication. P53 is usually not expressed in high Essentially, the peptide has been found to be
PROTOCOL: degrees in normal cells. Through blocking its cytotoxic to human cancer cells while having no
Content & Potency: 250mg/ml solution provided in a 10ml vial. inhibition via mdm2 protein modulators, we can effect on healthy cells and is functional almost
Suggested dosage: Inject 2mg/kg subcutaneosly twice weekly for 6 weeks. make sure P53 is expressed. Thus, cancer cells can across all cancer cell types.

CLINICAL RESEARCH: PROTOCOL:

Intra-articular injection pentosanpolysulphate results in increased hyaluronan molecular weight in joint fluid. Content & Potency: 5mg/ml solution provided in a 5mL vial.
The influence of an oversulphated glycosaminoglycan, after a series of four to six intra-articular injections of this
Suggested dosage: Inject 0.2ml to 0.4mL subcutaneously three times daily.
pentosanpolysulphate, on hyaluronan metabolism of the glycosaminoglycan. No increases in hyaluronan synthesis
synovial lining cell was studied in vivo in human
volunteers. Significant increases in the mean degree of
rates were observed. Repeated administration of the drug
did not cause any inflammation or bleeding in the joint
CLINICAL RESEARCH:
polymerisation of the hyaluronan chains were observed cavity. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2
in their membranes.
Clin Exp Rheumatol. 1992 May-Jun;10(3):249-54. The anticancer peptide PNC-27, which contains an untransformed cell lines. In colocalization experiments, we
HDM-2-binding domain corresponding to residues 12-26 find that PNC-27 binds to cell membrane-bound HDM-
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
of p53 and a transmembrane-penetrating domain, has been 2. We further transfected a plasmid expressing full-length
found to kill cancer cells (but not normal cells) by inducing HDM-2 with a membrane-localization signal into
membranolysis. We find that our previously determined untransformed MCF-10-2A cells not susceptible to PNC-
3D structure of the p53 residues of PNC-27 is directly 27 and found that these cells expressing full-length HDM-
superimposable on the structure for the same residues 2 on their cell surface became susceptible to PNC-27. We
bound to HDM-2, suggesting that the peptide may target conclude that PNC-27 targets HDM-2 in the membranes
HDM-2 in the membranes of cancer cells. We now find of cancer cells, allowing it to induce membranolysis of
significant levels of HDM-2 in the membranes of a variety these cells selectively.
of cancer cells but not in the membranes of several

Sarafraz-Yazdi, Ehsan et al. “Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their
membranes.” Proceedings of the National Academy of Sciences of the United States of America vol. 107,5 (2010): 1918-23.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

40 41
 PT-141 PTD-DBM
Purity: >98% (HPLC on request) | Molecular Formula: C50H68N14010 Purity: >98% | Molecular Formula: C124H22N61O28S2
Molecular Weight: 1025.2 | Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH Molecular Weight: 3082.65 | Sequence: RRRRRRRRGGGGRKTGHQICKFRKC

DESCRIPTION: DESCRIPTION:
Bremelanotide(PT-141) was developed from the arousal disorder). Unlike Viagra and other related
PTD.-DBM is a topical hair product which recently created peptide which interferes with
peptide hormone Melanotan II. In initial testing, medications, it does not act upon the vascular system,
helps activate the Wnt-Beta-catenin pathway via the binding process of CXXC5 and Dishevelled.
Melanotan II induced darkening of skin pigment, but but directly increases sexual desire via the nervous
additionally caused sexual arousal and spontaneous system. It is estimated that 43% of women (30 inhibition of CXXC5. This articular pathway has Studies have proven that PTD-DBM is
erections as unexpected side effects in nine out of million is the US) suffer from sexual dysfunction and been proven to help rescue DHT induced hair significantly more effective at inducing hair
the ten original male volunteer test subjects. Further 30 million men suffer from ED, with incidence follicle miniaturization. CXXC-type zinc finger neogenesis when combined with Valproic Acid,
testing in animals showed Bremelanotide to induce increasing 2-3 fold between ages 40-70. protein 5 (CXXC5) is a negative which stimulates the Wnt/β-catenin pathway
lordosis (a sexual mating behavior) and subsequently Bremelanotide currently has no contraindications and regulator of the Wnt/β-catenin pathway which when applied topically. This combination should

TAILOR MADE COMPOUNDING

tested for its effect in humans. Although, most of is 80% effective in men don’t respond to Viagra or has been associated with hair restoration and be applied post-microneedling to take advantage
the research has been targeted to women with female Cialis. For women, it causes a 50% increase in wound healing. Follicle development and of the follicle development that is induced
sexual dysfunction an it is effective medication in sexually satisfying experiences. If FDA approved, it formation can impeded by CXXC5 binding with naturally by the wound healing process.
treating sexual dysfunction in both men (erectile will have the trade name Ayleesi. the protein Dishevelled. PTD-DBM is a very
dysfunction or impotence) and women (sexual

PROTOCOL: PROTOCOL:
Content & Potency: 0.5% solution in a 20ml spray bottle.
Content & Potency: 10mg/ml subcutaneous injection provided in a 2ml vial. Suggested dosage: Apply topically to area of intended hair regrowth once daily.
Suggested dosage: Inject 0.2mL subcutaneously as needed, 30 minutes to 6 hours prior to sexual
activity. The initial dose will establish a time frame for response. Men should start at 0.1ml and titrate
up to and not exceed 0.2ml. Women should start at 0.2ml dosing protocol. CLINICAL RESEARCH:
CXXC5 is a negative-feedback regulator of the Wnt/ β-catenin pathway involved in osteoblast differentiation
CLINICAL RESEARCH: The positive roles of the Wnt/ β-catenin pathway in severe gross developmental abnormalities. CXXC5 exerted
osteoblast differentiation and bone mineral density (BMD) a negative-feedback effect on the Wnt/ β-catenin pathway
Melanocortins in the treatment of male and female sexual dysfunction.
maintenance have been clearly demonstrated in both via Wnt-dependent binding to Dishevelled (Dvl) during
Melanocortinergic agents are currently being investigated therapy for erectile dysfunction. Studies using animal animal experiments and clinical investigations. CXXC osteoblast differentiation. Suppression of the Dvl–CXXC5
for a possible therapeutic role in male and female sexual models have demonstrated that pre-copulatory behaviors finger protein 5 (CXXC5), a recently identified negative interaction using a competitor peptide resulted in the
dysfunction. These investigations were sparked by in female rats analogous to sexual arousal are evoked, and regulator of the Wnt/ β-catenin pathway, showed altered activation of the Wnt/ β-catenin pathway and osteoblast
findings that systemic administration of a synthetic analog preliminary clinical data also suggest a role in promoting cellular localization and function, which were dependent differentiation, and accelerated thickness growth of ex
of alpha-MSH, MT-II, causes penile erections in a variety sexual desire and arousal in women. Based on on the cell type in previous studies. However, the in vivo vivo-cultured calvariae. Overall, CXXC5 is a negative-
of species, including humans. Several other bremelanotide clinical experience, administration of a function of CXXC5 has not been clearly investigated yet. feedback regulator induced by Wnt/ β-catenin signaling
melanocortinergic agents including HP-228, THIQ, and melanocortin agonist is well tolerated and not associated Here, we characterized CXXC5 as a negative regulator of that inhibits osteoblast differentiation and bone formation
bremelanotide (PT 141) have since been shown to have the hypotension observed with phosphodiesterase-5 osteoblast differentiation and bone formation. Deficiency via interaction with Dvl.
erectogenic properties thought to be due to binding inhibitors currently used to treat erectile dysfunction. This of CXXC5 resulted in elevated BMD in mice without any
to melanocortin receptors in the central nervous system, review discusses investigations of melanocortin agonists for
particularly the hypothalamus. Bremelanotide, a nasally the treatment of sexual dysfunction with emphasis on CXXC5 is a negative-feedback regulator of the Wnt/ β-catenin pathway involved in osteoblast differentiation
administered synthetic peptide, is the only proposed sites and mechanisms of action in the central
melanocortinergic agent that has been clinically studied in nervous system that appear to be involved in Kim, Hyun-Yi & Yoon, Juyong & Yun, J-H & Cho, K-W & Lee, S-H & Rhee, Yumie & Jung, H-S & Lim, Hwan Jung & Lee, Hyuk & Choi, J &
both males and females. Data from Phase II clinical trials of melanocortinergic modulation of sexual function. Heo, J-N & Lee, W & No, Kyoung Tai & Min, D & Choi, K-Y. (2015). CXXC5 is a negative-feedback regulator of the Wnt/ β-catenin pathway
involved in osteoblast differentiation. Cell death and differentiation. 22.
bremelanotide support the use of melanocortin based
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
Shadiack, Annette & D Sharma, Shubh & C Earle, Dennis & Spana, Carl & J Hallam, Trevor. (2007). Melanocortins in the Treatment of Male and
Female Sexual Dysfunction. Current topics in medicinal chemistry. 7. 1137-44.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

42 43
 RG3, Methylcobalamin, NAD+ Sarms LGD-4033
Purity: >98% | Molecular Formula: C14H12F6N2O
RG3- Purity: >99.5% | Molecular Formula: C42H72O13
Molecular Weight: 338.25/mol | Sequence: Non-Peptide
Molecular Weight: 85.025 g/mol | Sequence: Non-Peptide
Methylcobalamin- Molecular Formula: C63H91CoN13O14P
Molecular Weight: 1344.4 g/mol | Sequence: Non-Peptide DESCRIPTION:
NAD+ Molecular Formula: C21H27N7O14P2 Selective Androgen Receptor Modulators many of the same positive effects on muscle
Molecular Weight: 663.43 g/mol | Sequence: Non-Peptide (SARMs) provide the benefits of traditional tissue. SARMs can be administered in an
anabolic/androgenic agents such as testosterone injectable dosage form and are absorbed orally are
DESCRIPTION: (including increased muscle mass, fat loss, and with no liver toxicity as with most oral steroids.
bone density), while having lower unwanted side The anabolic effect has been measured to be
RG3 is a Panax ginseng that has been used in oriental RG3 has been shown to reduce chronic
countries for its pharmacologic effects, such as neurodegenerative inflammation, the effects characteristic of oral anabolics roughly the same or greater than testosterone. It
antidiabetic, neurological, and anti- inflammatory proinflammatory cytokine, interleukin-6 (IL-6) and (aromatization / increased DHT). By has also been shown to produce dose-dependent
TAILOR MADE COMPOUNDING

activities. Neuroinflammation is associated with interleukin-1β (IL-1β ), and tumor necrosis factor-α stimulating the androgen receptor, SARMs can increases in bone mineral density and mechanical
activation of the central nervous system (CNS) glia (TNF-α). Methylcobalamin and NAD+ are combined provide a similar therapeutic outcome to strength, decrease body fat and increase lean body
with significant cytokine and chemokine production, with RG3 to enhance its effects. Target treatments androgen therapy without any increase in mass. LGD-4033 is a relatively new SARM on
infiltration of immune cells, edema, increased blood- for RG3/Methylcobalamin/NAD+ include aging, androgen levels. SARMs have the potential to the market. It can be dosed orally at low doses
brain barrier (BBB) permeability and breakdown. traumatic brain injury (TBI), Alzheimer’s, diabetes, take the place of androgens, and therefore exert and has a very strong anabolic effect.
Ginsenoside 20(S) RG3 is one of the many active atherosclerosis, and hypertrophic scar formation. RG3
ingredients of ginseng saponins. RG3 is a ginseng
known for aiding chronic inflammation. Specifically,
also has promising views for treatment in ovarian
cancer, prostate cancer, and other cancers as well. PROTOCOL:
Content & Potency: 0.5mg capsule provided in a quantity of 32.
PROTOCOL: Suggested dosage: Take one capsule once daily for 32 days should be cycled (one month on, one
month off).
Content & Potency: 2/2/50mg/mL provided in both a 15ml and 30 ml nasal spray applicator.
Suggested dosage: Instill one spray intranasally 2-4 times daily.
CLINICAL RESEARCH:
CLINICAL RESEARCH: The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor
Modulator, in Healthy Young Me
Suppressive Effect of Ginsenoside Rg3 against Lipopolysaccharide- Induced Depression-Like Behavior and
LGD-4033 was well tolerated. There were no drug-related and triglyceride levels. Follicle-stimulating hormone and
Neuroinflammation in Mice
serious adverse events. Frequency of adverse events was free testosterone showed significant suppression at 1.0-mg
Ginsenoside Rg3 (Rg3), a major active ingredient enriched mRNA expression of cytokines and indoleamine-2, 3- similar between active and placebo groups. dose only. Lean bodymass increased dose dependently, but
in red ginseng, possess well-confirmed dioxygenase (IDO). These central benefits were partially Hemoglobin, prostate-specific antigen, aspartate fat mass did not change significantly. Hormone levels and
immunoregulatory effects. Immune disturbance is a linked to the regulation of microglia activation and nuclear aminotransferase, alanine aminotransferase, or QT intervals lipids returned to baseline after treatment discontinuation.
common trigger and aggravating factor in depression. The factor kappa B (NF-kB) pathway. In addition, Rg3 did not change significantly at any dose. LGD-4033 had a LGD-4033 was safe, had favorable pharmacokinetic profile,
aim of this study was to explore the effects on Rg3 on significantly reduces LPS-induced elevation of interleukin-6 long elimination half-life and dose-proportional and increased lean body mass even during this short period
lipopolysaccharides (LPS)-induced depression-like (IL-6) and tumor necrosis factor-α (TNF-α) in plasma, accumulation upon multiple dosing. LGD-4033 without change in prostate-specific antigen. Longer
behavior in mice and the involvement of immune and restored the systemic balance of tryptophan-ky- administration was associated with dose-dependent randomized trials should evaluate its efficacy in improving
regulation. Pretreatment with Rg3 (i.g., 20 and 40 mg/ nurenine metabolism. Taken together, our results suppression of total testosterone, sex hormone – physical function and health outcomes in select
kg) effectively ameliorated LPS (i.p., 0.83 mg/kg) induced demonstrated the Rg3 was effective in ameliorating binding globulin, high density lipoprotein cholesterol, populations.
body weight loss, anorexia, and immobility time in both depressive-like behavior induced by immune activation,
the tail suspension test and the forced swimming test. adding new evidence to support its health benefits by Basaria, Shehzad & Collins, Lauren & Dillon, Edgar & Orwoll, Katie & Storer, Thomas & Miciek, Renee & Ulloor, Jagadish & Zhang, Anqi & Eder,
Rg3 attenuated the disturbed turnover of tryptophan and immunoregulation. Richard & Zientek, Heather & Gordon, Gilad & Kazmi, Syed & Sheffield-Moore, Melinda & Bhasin, Shalender. (2012). The Safety, Pharmacokinetics,
serotonin in the hippocampus, accompanied by decreased and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. The journals of gerontology.
Series A, Biological sciences and medical sciences. 68.
Kang, An & Xie, Tong & Zhu, Dong & Shan, Jinjun & di, liuqing & Zheng, Xiao. (2017). Suppressive Effect of Ginsenoside Rg3 against
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
Lipopolysaccharide-Induced Depression-Like Behavior and Neuroinflammation in Mice. Journal of Agricultural and Food Chemistry. 65.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

44 45
 Selank Semax
Purity: >98% (HPLC on request) | Molecular Formula: C37H51N9O10S
Molecular Weight: 813.92g/mol | Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
Purity: >98% (HPLC on request) | Molecular Formula : C33H57N11O9
Molecular Weight: 751.89 g·mol-1 | Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro DESCRIPTION:
DESCRIPTION: It is well known that ACTH/MSH-like peptides
(melanocortins) exert pleiotropic non-hormonal
prescribed it for many conditions like anxiety,
memory improvement, ischemic events, stroke,
Selank is another ACTH/MSH-like peptide of the dependence. Experiments have also demonstrated the actions among their larger activities. nerve regeneration, ADHD, opioid withdrawal,
melanocortin class most closely related to the analog effectiveness of Selank in preventing the accumulation Melanocortins affect learning processes and and even chronic diseases such as ALS,
tufstin. While traditionally prescribed for anxiety and of body fat (i.e., weight gain) with simultaneous exploratory behavior, regeneration and Parkinson’s, and Alzheimer’s. Some doctors use
depression, it has been known to be effective in activation of the functional state of the development, nociceptive and inflammatory it as a preventative measure to protect against
many other treatments related to immune anticoagulation system in development of the
processes, accelerate nerve regeneration and chronic disease and to acutely help improve
modulation, anticoagulation, PTSD, ADHD, and metabolic syndrome.
improve neuromuscular performance. Together memory and learning processes. It also has a

TAILOR MADE COMPOUNDING

metabolic syndromes. Selank has pronounced Furthermore, decreased blood glucose levels have been
anxiolytic activity and acts as a stable observed with chronic treatment of this peptide. The these classes of peptides control many behaviors marked antithrombotic and fibrinolytic effect and
neuropsychotropic, antidepressant, and anti-stress peptide Selank, like the drug Semax, induces such as regulating attention, processes of a gastric protective effect. It has also been
drug that relieves aggression and fear reaction in anticoagulant and hyperglycemia effects possibly due learning, and memory formation as a result of suggested in literature that due to its effect on
different animal species. Selank also has a nootropic to the presence of the same amino acid sequence, their pronounced effect on CNS functions. carboxypeptidase it can also increase physical
action, which positively influences the formation of Pro-Gly-Pro, in its structure. Thus, Selank can be used Heptapeptide SEMAX (MEHFPGP) is the performance and adaptation capacities in
memory and learning processes, and marked as a broad-spectrum therapeutic agent for the analogue of ACTH (4-10) that has prolonged exposure to high intensity exercise. At its higher
immunomodulatory activity. Clinical studies have treatment of metabolic syndrome. neurotropic activity and thus is a good candidate doses, .5mg/kg can even be analgesic.
shown that the effect of selank is similar to that of Often prescribed for: Anxiolytic, Immune for medical therapy. Currently this peptide is
tranquilizers at low doses, but is not accompanied by improvement, gastric protection, as a preventative successfully used in treatment of patients with Often prescribed for: Anti-Thrombosis, ADHD/
the unwanted side effects of benzodiazepine weight gain/metabolic syndrome, and with opioid
pathologies related to brain circulation Learning, Gastric protection, Physical exertion
tranquilizers such as amnesia, withdrawal, or and alcohol withdrawal/ dependence.
dysfunction and with different intellectual- improvement pain, Metal toxicities.
amnestic problems of the CNS. Doctors have
PROTOCOL:
Content & Potency: 7500mcg/ml provided in a 3ml nasal spray applicator. PROTOCOL:
Suggested dosage: Spray 1 to 2 sprays intranasally once daily.
Content & Potency: 7500mcg/ml provided in a 3ml nasal spray applicator.
Suggested dosage: Spray two sprays intranasally once daily.
CLINICAL RESEARCH:
P-1114 - Rapid and Slow Response During Treatment of Generalized Anxiety Disorder with Peptide
Anxiolytic Selank
CLINICAL RESEARCH:
The Nootropic and Analgesic Effects of Semax Given via Different Routes
Results: 40% of patients were rapid responders (RR) and score from 16.1[7.2] to 6.2[4.7] were achieved at Day 14,
characterized by abrupt reduction of whole set of p< 0.01. In contrast to CR, RR demonstrated The heptapeptide Semax (MEHFPGP) is an analog of the in a hindpaw compression test. The results showed that i.p.
symptoms in first 1-3 Days. At the Day 3 Hamilton obviousEEG-reaction after single dose (900 μg) with fragment ACTH(4–10) with long-lasting actions.The aim Semax had nootropic and analgesic actions. Dose-response
Anxiety Rating Scale (HARS) mean total score [SD] increase of beta-rhythm, decrease of theta- and low of the present work was to study the effects of Semax on characteristics were different for these different effects.
reduced from 20.3[11.9] to 7.0[2.9] (p< 0.01). 60% of frequencies of alpha-rhythm (all p< 0.05). Initially RR learning ability and pain sensitivity in white rats given Intranasal Semax was more effective in improving learning
patients responded gradually(conventional responders - and CR significantly differed by the score of asthenic and different doses via the intraperitoneal and intranasal routes. in animals than i.p. Semax but had no effect on pain
CR). Clinically significant changes of mean HARS total cognitive symptoms (p< 0.05). The nootropic effects of Semax were studied in a test based sensitivity. Our results provide evidence that different
on the acquisition of a conditioned passive avoidance mechanisms and brain structures are involved in mediating
Syunyakov, Timur & S Teleshova, E & G Neznamov, G & Bochkarev, Vitaly. (2012). P-1114-Rapid and slow response during treatment of generalized reaction to pain stimulation. Pain sensitivity was assessed the nootropic and analgesic effects of Semax.
anxiety disorder with peptide anxiolytic selank. European Psychiatry. 27.
D.M, Manchenko & N.Yu, Glazova & Levitskaya, Natalia & L.A, Andreeva & , KamenskiiA.A & N.F, Myasoedov. (2012). The Nootropic and
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
Analgesic Effects of Semax Given via Different Routes. Neuroscience and Behavioral Physiology. 42. 264-270.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

46 47
 Tesamorelin Tesofensine
Purity: >98% (HPLC on request) | Molecular Formula : C221H366N72O67S Purity: >98% (HPLC on request) | Molecular Formula: C17H23Cl2NO
Molecular Weight: 5135.77 | Sequence: trans-hexenoyl-acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn- Molecular Weight: 3.277 g/mol | Sequence: Non-Peptide
Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-LeuGln-Asp-Ile-Met-Ser-Arg-Gln-
Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 DESCRIPTION:
Tesofensine is serotonin-noradrenaline-dopamine Tesofensine (TE) increases near transmission of
DESCRIPTION: reuptake inhibitor which was originally studied 3 monoaminergic neurotransmitters in the brain.
Tesamorelin is a growth hormone releasing thickness (cIMT), visceral adipose tissue (VAT), for its effect on Parkinson’s and Alzheimer’s. These neurotransmitters are serotonin, no
hormone analog that increases IGF-1 levels in and c-reactive protein (CRP). It has not been Unfortunately, its exploration for these repinephrine, and dopamine which help
men and women, by an average of 181 linked to significantly affect other pituitary indications were limited because the patients regulate energy balance and are linked to obesity
micrograms/liter. It binds to and stimulates hormones and their respective mechanisms in starting losing too much weight. Since then, the and depression.On average, its 6 month weight
GHRH receptors with similar potency as the body. Additionally, it can improve cognitive tesofensine has been studies as we way to treat loss results from a phase 2b clinical trial resulted
TAILOR MADE COMPOUNDING

endogenous GHRH. It has a host of other function for healthy seniors and patients with an obesity via its ability to reduce appetite. This in a weight loss of around 25 pounds.
benefits including nootropic effects and reducing increased risk of Alzheimer’s disease, due to mild medication indirectly stimulates the cholinergic
triglycerides. Tesamorelin has subsequently been cognitive impairment. system and showed to be more successful than
shown to decrease carotid intima-media average weight loss medication.

PROTOCOL: PROTOCOL:
Content & Potency: 1mg lyophilized subcutaneous injectables presented in a quantity of 24 vials Content & Potency: 500mcg capsule provided in a quantity of 30 capsules.
with 10ml of sterile water for injection for reconstitution. Suggested dosage: Take 1 capsule by mouth once daily in the morning.
Suggested dosage: Reconstitute each vial prior to injection with 0.6ml sterile water for injection,
inject 0.5ml subcutaneously before bed 6 out of 7 days 90 minutes after last food intake. CLINICAL RESEARCH:
CLINICAL RESEARCH:
Effects of Tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised,
double-blind, placebo-controlled trial
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with Weight-loss drugs produce an additional mean weight ClinicalTrials.gov, number NCT00394667. 161 (79%)
abdominal fat accumulation loss of only 3-5 kg above that of diet and placebo over 6 participants completed the study. After 24 weeks, the mean
Treatment of HIV patients with daily tesamorelin, a growth adverse events during the extension phase was comparable months, and more effective pharmacotherapy of obesity is weight loss produced by diet and placebo was 2.0% (SE
hormone-releasing factor analogue, for 26 weeks resulted with the initial phase. Changes in glucose parameters over needed. We assessed the efficacy and safety of 0.60). Tesofensine 0.25 mg, 0.5 mg, and 1.0 mg and diet
in a significant decrease in visceral adipose tissue (VAT) 52 weeks were not clinically significant and similar to those tesofensine-an inhibitor of the presynaptic uptake of induced a mean weight loss of 4.5% (0.87), 9.2% (0.91),
and improvement in lipids. The objective of the 26-week after 26 weeks. The change in VAT was sustained at -18% noradrenaline, dopamine, and serotonin-in patients with and 10.6% (0.84), respectively, greater than diet and
extension phase was to evaluate long-term safety and effects over 52 weeks of treatment (P < 0.001 versus baseline) as obesity. We undertook a phase II, randomised, placebo (p<0.0001). The most common adverse events
of tesamorelin. HIV patients with central fat accumulation was the change in triglycerides (-51 mg/dl, P < 0.001 versus double-blind, placebo-controlled trial in five Danish caused by tesofensine were dry mouth, nausea,
in the context of antiretroviral therapy were randomized to baseline). Similar sustained beneficial effects were seen for obesity management centres. After a 2 week run-in phase, constipation, hard stools, diarrhoea, and insomnia. After 24
tesamorelin 2 mg (n = 273) or placebo (n = 137) s.c. daily total cholesterol, but high-density lipoprotein decreased 203 obese patients (body-mass index 30-</=40 kg/m(2)) weeks, tesofensine 0.25 mg and 0.5 mg showed no
for 26 weeks. At week 26, patients originally on minimally over 52 weeks. Upon discontinuation of were prescribed an energy restricted diet and randomly significant increases in systolic or diastolic blood pressure
tesamorelin were rerandomized to 2 mg tesamorelin (T-T tesamorelin, VAT reaccumulated. Treatment with assigned with a list of randomisation numbers to treatment compared with placebo, whereas heart rate was increased
group, n = 154) or placebo (T-P group, n = 50), whereas tesamorelin was generally well tolerated and resulted in with tesofensine 0.25 mg (n=52), 0.5 mg (n=50), or 1.0 by 7.4 beats per min in the tesofensine 0.5 mg group
patients originally on placebo were switched to sustained decreases in VAT and triglycerides over 52 weeks mg (n=49), or placebo (n=52) once daily for 24 weeks. The (p=0.0001). Our results suggest that tesofensine 0.5 mg
tesamorelin (P-T group, n = 111). Safety included adverse without aggravating glucose. Though effects on VAT are primary outcome was percentage change in bodyweight. might have the potential to produce a weight loss twice that
events and glucose parameters. Tesamorelin was generally sustained during treatment for 52 weeks, these effects do Analysis was by modified intention to treat (all randomised of currently approved drugs. However, these findings of
well tolerated. The prevalence of adverse events and serious not last beyond the duration of treatment. patients with measurement after at least one dose of study efficacy and safety need confirmation in phase III trials.
drug or placebo). The study is registered with
Falutz, Julian & Allas, Soraya & Mamputu, Jean-Claude & Potvin, Diane & Kotler, Donald & Somero, Michael & Berger, Daniel & Brown, Stephen
& Richmond, Gary & Fessel, Jeffrey & Turner, Ralph & Grinspoon, Steven. (2008). Long-term safety and effects of tesamorelin, a growth hormone-
Astrup, Arne & Madsbad, Sten & Breum, Leif & J Jensen, Thomas & Peter Kroustrup, Jens & Meinert Larsen, Thomas. (2008). Effect of tesofensine
releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (London, England). 22. 1719-28.
on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 372.
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
48 49
 Tetradecylthioacetic Acid (TTA) Thymosin Alpha-1
Purity: >98% (HPLC on request) | Molecular Formula: C129H215N33O55
Purity: >98% (HPLC on request) | Molecular Formula : C16H32O2S
Molecular Weight: 3108.28 | Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-
Molecular Weight: 288.49 g/mol | Sequence: Non-Peptide
Lys-Asp-Leu-Lys-GluLysLys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH

DESCRIPTION: DESCRIPTION:
Tetradecylthioacetic Acid, otherwise known as Activation of PPAR-alpha promotes uptake,
Thymosin α-1 is a major component of approval status. It is widely used and studied in
TTA, is a PPAR-alpha activator. Although similar utilization, and catabolism of fatty acids by
Thymosin Fraction 5 and is responsible for multiple types of cancer and viral illnesses. Some
in structure to an omega-3 fatty acid, it cannot be upregulation of genes involved in fatty acid
restoring and modulating immune function, physicians are using thymosin for chronic fatigue
utilized for energy and thus has no relevant transport, fatty acid binding and activation, and
particularly cell mediated immune function. and Lyme disease as well as autoimmune function
caloric value to humans. PPAR-alpha is a peroxisomal and mitochondrial fatty acid.
Recent studies showed that Thymosin Alpha-1 as well.
transcription factor and a major regulator of lipid β-oxidation. The clearing of fat from the blood
molecule increased major histocompatibility
metabolism in the liver. PPAR-alpha is activated causes a drop in lipoproteins and a lowering of

TAILOR MADE COMPOUNDING

complex (MHC) class-1 and Toll-like receptor TA 1 is thought to modulate the immune system
under conditions of energy deprivation and is LDL cholesterol. TTA has also been shown to
expression as well as cytokine production, by augmenting T-cell function. TA1 may affect
necessary for the process of ketogenesis, a key decrease blood pressure and exert a mild anti-
suggesting its immunoregulatory role. thymocytes by stimulating their differentiation
adaptive response to prolonged fasting. oxidant effect.
or by converting them to active T cells. TA1 is
It is an FDA approved medication under the rapidly absorbed, achieving peak serum
PROTOCOL: trade name zadaxin after it received orphan drug concentrations within two hours.
Content & Potency: 200mg capsules provided in quantities of 90 capsules.
Suggested dosage: Take 1 capsule by mouth 3 times daily. PROTOCOL:
Content & Potency: 1 x 5mL at 3000 mcg/mL ready-to-inject subcutaneous.
CLINICAL RESEARCH: Suggested dosage: Inject .15mL subcutaneously once daily until vial is empty (1 month
supply) or inject 1.6mg 2 x 1 week.
Dietary supplementation of tetradecylthioacetic acid increases feed intake but reduces body weight gain and

CLINICAL RESEARCH:
dipose depot sizes in rats fed on high-fat diets
Despite higher feed intake during the final 2 weeks of the was enhanced in lard plus TTA-fed rats. Hepatic UCP3
study, rats fed on TTA gained less body weight than was expressed ectopically both at protein and mRNA level Thymosin Alpha 1: Biological activities, applications and engineering production
lard-fed rats and had markedly decreased subcutaneous, (>1900-fold), whereas Ucp1 mRNA was increased 30-fold Thymosin alpha 1 (Tα1), a 28-amino acid peptide, was production of this peptide. So far, Tα1 used in clinic is
epididymal, perirenal and mesenteric adipose depots. The in epididymal and 90-fold in mesenteric fat after lard plus first described and characterized from calf thymuses in synthesized using solid phase peptide synthesis. Here, we
effects of TTA feeding with reduced body weight gain and TTA feeding. 1977. This peptide can enhance T-cell, dendritic cell (DC) summarize the genetic engineering methods to produce
energy efficiency (weight gain/feed intake) started between Conclusion: Our data support the hypothesis that TTA and antibody responses, modulate cytokines and Tα1 using prokaryotic or eukaryotic expression systems.
day 10 and 13. Body contents of fat, protein and water feeding may increase hepatic fatty acid β-oxidation, and chemokines production and block steroid-induced The effectiveness of these biological products in increasing
were reduced after feeding lard plus TTA, with a stronger thereby reduce the size of adipose tissues. The apoptosis of thymocytes. Due to its pleiotropic biological the secretion of cytokines and in promoting lymphocyte
decrease in fat relative to protein. Plasma lipids, including functional importance of ectopic hepatic UCP3 is activities, Tα1 has gained increasing interest in recent years proliferation were investigated in vitro studies. This opens
Non-Esterified Fatty Acids (NEFA), were significantly unknown but might be associated with enhanced energy and has been used for the treatment of various diseases the possibility for biotechnological production of Tα1 for
reduced, whereas fatty acid β-oxidation in liver and heart expenditure and thus the reduced feed efficiency. in clinic. Accordingly, there is an increasing need for the the research and clinical applications.

Wensaas AJ, Rustan AC, Rokling-Andersen MH, Caesar R, Jensen J, Kaalhus O, Graff BA, Gudbrandsen OA, Berge RK, Drevon CA. Li, Juan Jenny et al. “Thymosin alpha 1: Biological activities, applications and genetic engineering production.” Peptides 31 (2010): 2151-2158.

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info. A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

50 51
 Thymosin Beta VIP
Purity: >98% (HPLC on request) | Molecular Formula : C212H350N56O78S Purity: >98% (HPLC on request) | Molecular Formula: C147H237N43O43S
Molecular Weight: 4963.506 g/mol | Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-lle-Glu- Molecular Weight: 3326.831 g/mol | Sequence: HSDAVFTDNYTRLRKQMAVKKYLN
Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-LysThr-Glu-Thr-Gin-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu- SILN-NH2
Thy-lleGlu-Gin-Glu-Lys-Gin-Ala-Gly-Glu-Ser
DESCRIPTION:
DESCRIPTION: Vasoactive intestinal polypeptide (VIP) is a paracrine mediator. Therapeutically, it is often
Thymosin is a hormone secreted from the found to play an important role in protection, naturally produced neuropeptide that functions dosed nasally in patients with mold toxicity and
thymus. Its primary function is to stimulate regeneration and remodeling of injured or as a neuromodulator and neurotransmitter. It is a other biotoxin illnesses. In these patients,
the production of T cells, which are an important damaged tissues. The gene for Tβ4 has also been potent vasodilator, regulates smooth muscle exogenous administration can help support
part of the immune system. Thymosin also assists found to be one of the first to be upregulated activity, epithelial cell secretion, and blood flow healthy hormone levels, works to limit
in the development of B cells to plasma cells to after injuries. Thymosin Beta 4 is currently being in the gastrointestinal tract. As a chemical inflammation, regulates the immune system, and
TAILOR MADE COMPOUNDING

produce antibodies. The predominant form of trialed as a potential therapy for HIV, AIDS, and messenger, it functions as a neurohormone and help in the healing activity of the brain.
Thymosin, Thymosin Beta 4, is a member of a Influenza. Thymosin Beta 4 is most often
highly conserved family of actin monomer-
sequestering proteins. In addition to its role as
prescribed for acute injury, surgical repair and for
senior athletes. It has most recently been shown
PROTOCOL:
a major actin-sequestering molecule, Thymosin to help regrow hair in addition to PRP. Content & Potency: 500mcg/ml provided in a 12 ml nasal spray applicator.
Beta 4 plays a role in tissue repair. Tβ4 has been Suggested dosage: Instill 50mcg intranasally in alternating nostrils up to 4 times daily.

PROTOCOL: CLINICAL RESEARCH:

Content & Potency: 3000mcg/ml subcutaneous injection provided in a 5ml vial. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired
following exposure to water-damaged buildings
Suggested dosage: Inject 0.25ml subcutaneously daily for 20 days.
Exposure in water-damaged buildings (WDB) to airborne CIRS-WDB illness who took replacement VIP in a nasal

CLINICAL RESEARCH:
bioaerosols including metabolic products of toxigenic spray for at least 18 months with confirmation of durable
fungi, bacteria and actinomycetes; and inflammagens, can efficacy and absence of significant side effects. These 20
Differential expression of the human thymosin-beta 4 gene in lymphocytes, macrophages, and granulocytes. lead to a persistent innate immune inflammatory illness. patients were similar in symptoms and lab findings to three
This illness, termed a chronic inflammatory response previously published cohorts involving 1829 patients and
A cDNA clone encoding human thymosin-beta 4 was blot analyses of different neoplastic B lymphocytes revealed syndrome (CIRS-WDB), is systemic with symptoms 169 controls. Dosage of VIP was titrated downwards from
isolated from a cDNA library prepared from peripheral that steady state levels of thymosin-beta 4 mRNA varid as a acquired from multiple organ systems. Treatment of four to zero doses a day to determine minimum effective
blood leukocytes of a patient with acute lymphocytic function of differentiation stage. Thymosin-beta 4 mRNA CIRS-WDB has progressed rapidly as a better dose, and re-titrated upwards for maximum improvement
leukemia. This clone contained the entire coding sequence levels were decreased in myeloma cells as are class II understanding of the inflammatory pathophysiology has over time. The trial showed that VIP therapy safely 1)
of 43 amino acid residues of thymosin-beta 4 and had an human leukocyte antigen, Fc receptor, and complement led to targeted, sequential therapies. The fundamental basis reduced refractory symptoms to equal controls; 2)
initiation codon and two termination codons. The amino receptor, suggesting a relationship between thymosin-beta of uncontrolled innate immune responses, the humoral corrected inflammatory parameters C4a, TGF beta-1,
acid and nucleotide sequences in the coding region were 4 and the immune response. Thymosin-beta 4 mRNA deficiency of regulatory neuropeptides melanocyte VEGF, MMP9; 3) corrected estradiol, testosterone and
well conserved between rat and human. Nine of 132 was more highly expressed in mature granulocytes than in stimulating hormone (MSH) or vasoactive intestinal 25-OH Vitamin D; 4) returned pulmonary artery systolic
nucleotides were different in the coding sequences (93% immature blastic cells. Treatment of THP-1 cells, a human polypeptide (VIP), seen in over 98% of patients, has not pressure (PASP) during exercise to normal; and 5)
homology), but the deduced amino acid sequences were monocytic cell line, with recombinant human interferon- consistently responded to any treatment modality. Use of enhanced quality of life in 100% of trial patients.
identical. No signal peptide was found in the deduced lambda reduced the levels of thymosin-beta 4 mRNA. Its replacement VIP has been attempted anecdotally; VIP Subsequent identification of correction of T-regulatory cell
protein sequence. Human thymosin-beta 4 mRNA, level decreased after differentiation of THP-1 cells into Ia+ replacement therapies show promise in short term studies levels supports the potential role of VIP in both innate and
approximately 830 nucleotides in length, was about 30 macrophages, but increased after differentiation of HL-60 but longer therapies have not been attempted. Here we adaptive immune function.
nucleotides larger than rat thymosin-beta 4 mRNA. cells into Ia- macrophages. The pattern of thymosin-beta report an open label trial of 20 patients with refractory
Expression of the human thymosin-beta 4 gene in various 4 gene expression suggests that it may play a fundamental
primary myeloid and lymphoid malignant cells and in a role in the host defense mechanism.
Ritchie C. Shoemaker, Dennis House, James C. Ryan
few human hemopoietic cell lines was studied. Northern
A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
H Gondo, J Kudo, J W White, C Barr, P Selvanayagam, G F Saunders The Journal of Immunology December 1, 1987, 139 (11) 3840-3848;

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.
52 53
 Zinc Thymulin
Purity: >98% (HPLC on request) | Molecular Formula: C33H54N12O15
Molecular Weight: 858.85 g/mol | Sequence: Non-Peptide

DESCRIPTION:
Thymulin is a nonapeptide produced by two to test its efficacy in the treatment of hair loss.
distinct epithelial populations in the thymus first The study indicated that topical treatment with
described by Bach in 1977. It requires zinc for zinc thymulin significantly increased hair growth
biological activity. The hormone is involved in over 6 months; further, there were no system-
T-cell differentiation and enhancement of T and ic or local side effects from the treatment. The
NK cell actions. Thymulin has neuroendocrine zinc thymulin metallo-peptide optionally also
effects as well. It follows a circadian rhythm and improves endogenous hair pigmentation. For
physiologically elevated ACTH levels correlate example, by stimulating melanogenesis in grey or
positively with thymulin plasma levels and vice greying hair.
versa. A recent study was done on Zinc Thymulin

PROTOCOL:
Content & Potency: Topical foam provided in a quantity of 50ml foaming applicator.
Suggested dosage: Apply 1ml (2 pumps) to scalp once daily at night.

CLINICAL RESEARCH:
An Analysis of the Safety and Efficacy of Topical Zinc-Thymulin to treat Androgenetic Alopecia
To assess the safety and efficacy of the metallopeptide index (HGI) of images under higher magnification for
zinc-thymulin (ZT) for treating androgenetic alopecia percentage changes of vellus, intermediate and terminal
(AGA). Previous in vitro studies have described that hair.
different thymic peptides can both increase and decrease ZT demonstrated no adverse systemic effects or local side
anagen (thymulin and thymosin beta-4, respectively). Zinc effects of redness or scalp irritation in any subject over a
is an essential element and serum zinc deficiency can cause total of 3,300 treatment days. Three subjects who were
hair loss. concurrently using minoxidil (N=2) and minoxidil /
Eighteen consecutive adult subjects were recruited, 17 finasteride (N=1) did not report any drug interaction with
males and 1 female, age range 35-90 years(mean 55.4, SD ZT. VAS hair assessment improvement was significant in
13.3) with a diagnosis of AGA, Norwood classification subjects who completed 6 months of treatment (P=0.045,
2-7, and hair loss duration range of 3-40 years (mean 15.8, t-test). HGI assessment showed a significant increase in the
SD 9.6). The trial duration for each subject ranged from number of newly observed intermediate hairs in previous
4-10 months. The test compound ZT was synthesized by “absent hair” regions (P<0.0001) with an average increase
standard Fmoc peptide protocols and administered in water of vellus type (32%) and intermediate type (23%) hairs at 6
based topical spray to the scalp.Baseline and after treatment months. Melanogenesis was observed in several subjects.
images for hair growth were graded by two blinded Topical applications of ZT demonstrated safety and
assessors using two validated scales: 1. numerical visual established efficacy for initiating and maintaining anagen to
analog scale (VAS) for global assessment 2. hair growth treat male pattern baldness when applied for >6 months.

Vickers ER

A full copy of all trials are available from Tailor Made Compounding Pharmacy. Please contact us for more info.

54 55
 DOSING
CHARTS
Please contact Tailor Made Compounding with dosing inquiries
for any products you may be interested in.

support@tailormadecompounding.com

56 57
 TIMING OF
PRODUCT QUANTITY DOSAGE APPLICATION INDICATION
DOSING TIMING OF
PRODUCT QUANTITY DOSAGE APPLICATION INDICATION
DOSING
2-Methoxyestradiol
Cancer CJC 1295
Capsule 3mL 100mcg daily Before bed Suppository
0.10mL Nightly, on an empty
3-Desoxy DHEA Injection 5mL at 2000mcg/mL 5 nights a week stomach before bed Subcutaneous injection GHRH

Capsules 100mg (30 capsules) 1 capsule daily Patient preference Oral Aromatase inhibitor CJC 1295/Ipamorelin
5-amino-1MQ 2mL (or 5ml) at
0.10mL Nightly, on an empty Subcutaneous GHRH,
30 minutes after oral Injection 1000mcg/
150mcg (.5ml) daily Subcutaneous 5 nights a week stomach before bed injection weight loss
Weight Loss & 1000mcg/mL
Injection 10ml at 300mg/ml administration of
for 20 days injection Performance
NAD+ precursor 2mL (or 5ml) at
0.10mL Nightly, on an empty Subcutaneous GHRH,
Amlexanox Injection 2000mcg/
5 nights a week stomach before bed injection weight loss
1000mcg/mL
Insulin sensitivity, 2mL (or 5ml) at
Capsules 40mg (90 capsules) 1 capsule TID Patient preference Oral 0.10mL Nightly, on an empty Subcutaneous GHRH,
weight loss Injection 2000mcg/
5 nights a week stomach before bed injection weight loss
2000mcg/mL
Ammonium Tetrathiomolybdate
DHH-B
Capsules 40mg (90 capsules) 1 capsule TID Patient preference Oral Cancer
Capsules 30 7.5mg capsules 1-2 capsules as needed Patient preference Oral Anti-Anxiety
Aniracetam
Dihexa
AMPA receptor
Capsules 375mg (60 capsules) 2 capsules daily Patient preference Oral modulator Patient Neurological
Capsules 5mg (30 capsules) 1-2 capsules daily Oral
(Neurogenic) preference function/repair
AOD-9604 Cream 30mL at 20mg/mL 4 clicks (1mL) daily Patient Transdermal Neurological
preference function/repair
Rubbed between
Cream 30mL at 600mcg/mL 4 clicks (1mL) daily Patient preference Repair DSIP
inner forearms
Injection 5mL at 1200mcg/mL 0.25mL daily Patient preference Subcutaneous Injection Repair 0.1mL daily, 2-3 Subcutaneous Endocrine
Injection 3mL at 1000mcg/mL Patient preference
times a week injection regulation, sleep
AOD 1000mcg/mL + 0.5mL-0.75mL Repair hyaline
Injection with HA Done by physician Intra-articular Enclomiphene
HA10mg/mL weekly for 4 weeks cartilage
Argireline/Leuphasyl Capsules 25mg (30 capsules) 1 capsule daily Patient preference Oral
Aromatase inhibitor
(Reproductive system)
0.5%/0.5% cream in Reduce wrinkle
Cream 1ml applied daily Patient preference Topical
30ml TopiClick depth and fine lines Epicatechin

Argireline/GHK-Cu/Leuphasyl Injection 100mg/ml 100mg (1ml) daily Patient preference Subcutaneous injection Sarcopenia,
into the abdomen Muscle gain
0.5%/0.2%/ 0.5% cream Reduce wrinkle
Cream 1ml applied daily Patient preference Topical Epitalon
in 30ml TopiClick depth and fine lines
BPC-157 Injection 5mL at 3000mcg/mL 0.1mL daily Patient preference Subcutaneous injection Repair tendon +
into site of injury ligaments
Subcutaneous injection Repair tendon +
Injection 3mL at 2000mcg/mL 0.15mL daily Patient preference Cerebrolysin
into site of injury ligaments
Subcutaneous injection Repair tendon + 4x10 mL at 1mL daily In the morning Subcutaneous injection Hormone regulation,
Injection 5mL at 2000mcg/mL 0.15mL daily Patient preference Injection
into site of injury ligaments 2.15.2mg/mL into the abdomen telomere extension

Capsules 500mcg (30 capsules) 1 capsule daily Patient preference Oral Repair bowel/gut Fat Loss Cream (Aminophylline/Glycrrhetinic Acid)

Cerebrolysin 60mL at 0.5%

2 pumps (1mL)
Cream aminophylline Patient preference Transdermal Fat reduction
4x10 mL at glycrrhetinic acid 2.5% twice daily
Injection 1mL daily Patient preference Subcutaneous injection Neurogenic
215mg/mL
FGL(l)
CJC 1295
5mL at 10mg/mL 0.25mL daily Patient preference Subcutaneous injection Neurogenic/
Injection
0.10mL Nightly, on an empty into the abdomen neurorestorative
Injection 2mL at 2000mcg/mL Subcutaneous injection GHRH
5 nights a week stomach before bed

58 Please contact Tailor Made Compounding with any questions about product dosing. Please contact Tailor Made Compounding with any questions about product dosing. 59
 TIMING OF
TIMING OF PRODUCT QUANTITY DOSAGE APPLICATION INDICATION
PRODUCT QUANTITY DOSAGE APPLICATION INDICATION DOSING
DOSING
Met-Enkephalin
FOXO4-DRI
Injection 10mg Lyophilized vial 10mg IV once weekly N/A Intravenous Cancer
Injection 10ml vial at 10mg/ml 300mcg/kg 3 doses every other day Intravenous Clear senescent
over 5 days cells MK-677
GHK-Cu Patient preference on Growth hormone
Capsules 25 mg (30 capsules) 1 capsule daily Oral
empty stomach IGF-1 increase
Injection 5mL at 10mg/mL 0.2mL daily Patient preference Subcutaneous injection Skin elasticity
MOTS-c
Foam Foam (for scalp Hair loss
50mL at 5mg/mL 2 pumps (1mL) daily Patient preference
application) Subcutaneous injection Energy,
Injection 4mL at 10mg/mL 1mL once weekly Patient preference
into the abdomen weight loss
IGF-1
Myristyl
Two 6.2mL vials at Subcutaneous injection Muscle building,
Injection 0.4mL-0.8ml daily Patient preference 100mcg/kg once Cholesterol
620mcg/mL into the abdomen weight loss Injection 5ml vial at 6mg/ml N/A Intravenous
weekly intravenously Reduction
IGF-1 LR3 NMN
Weight loss, muscle 10ml vial at 200mg (1ml) BID Anti-aging/
6.2mL at Post workout Subcutaneous injection building, autocrine Injection Patient preference Oral
Injection 0.4-0.8mL daily 200mg/ml subcutaneously Weight loss
100mcg/mL if applicable into the abdomen + paracrine hormone
signaling Anti-aging/
Capsule 30 capsules at 500mg 1 capsule daily Patient preference Oral
Weight loss
Ipamorelin
PEG-MGF
Injection 5mL at 2000mcg/mL 0.1mL daily Patient preference Subcutaneous GHRH, weight loss
5 days a week injection 0.1mL daily, Subcutaneous injection Building
Injection 5mL at 2000mcg/mL Patient preference
5 days a week into the abdomen muscle
iRGD
Pentosan Polysulfate (PPS)
Injection 10mL at 2.5mg/mL 40mcg/kg daily Dose alongside Subcutaneous injection Cancer
concurrent therapy Injection 10mL at 250mg/mL 250mg N/A Intramuscular Osteoarthritis

Kisspeptin-10 PNC-27

Subcutaneous injection Injection 5mL at 1000mcg/mL 2.5mg-5mg daily Patient preference Subcutaneous injection Cancer
Injection 5mL at 100mcg/mL 0.1mL daily Patient preference LH increase
into abdomen
PT-141 (Bremelanotide)
KPV
1-5 hours before sexual
0.2mL (female) Subcutaneous injection Erectile dysfunction,
30ml TopiClick at 0.5ml applied Injection 2mL at 10mg/mL activity (first dose will
Topical Patient preference Transdermal Cream Psoriasis as needed into abdomen libido
15mg/ml twice daily establish timing)

Liraglutide 0.1mL (male) 1-5 hours before sexual

Subcutaneous injection Erectile dysfunction,
Injection 2mL at 10mg/mL activity (first dose will
as needed into abdomen libido
Insulin resistance, establish timing)
Injection 5mL at 3600mcg/mL Varies Varies Subcutaneous injection
weight loss
PTD-DBM
LL-37
Spray a sufficient Applied after
Cream 5mL at 0.5% spray Transdermal Hair Loss
Varies with indication amount to cover area microneedling
Injection 5mL at 2000mcg/mL Physician preference Subcutaneous injection Antimicrobial
and patient
RG3
Melanotan I
One spray into each Patient preference Neurogenic/
Nasal 15mL Nasal
0.15mL daily with Subcutaneous injection nostril 2-4 times daily neurorestorative
Injection 5mL at 2000mcg/mL Patient preference Vitiligo
UVB light exposure into the abdomen One spray into each
Nasal 30mL Patient preference Nasal Neurogenic/
Melanotan I nostril 2-4 times daily neurorestorative

0.15mL daily for 1-2 RG3/Methylcobalamin/NAD+

0.15mL daily for Subcutaneous injection Libido, tanning,
Injection weeks then 0.25mL Patient preference
1-2 weeks into the abdomen weight loss One spray into each Patient preference Neurogenic/
weekly for maintenance Nasal 15mL Nasal
nostril 2-4 times daily neurorestorative

60 Please contact Tailor Made Compounding with any questions about product dosing. Please contact Tailor Made Compounding with any questions about product dosing. 61
 TIMING OF
PRODUCT QUANTITY DOSAGE APPLICATION INDICATION
DOSING

RG3/Methylcobalamin/NAD+

Nasal 30mL One spray into each Patient preference Nasal Neurogenic/
nostril 2-4 times daily neurorestorative
SARMS LGD-4033

Capsules 0.5mg (30 capsules) 1 month on, 1 month Patient preference Oral Muscle Building
off rotation

Selank

Subcutaneous injection
Injection 5mL at 1000mcg/1mL 0.1mL daily Patient preference Neurorestorative
into the abdomen
One spray into each
Nasal 3mL at 7500mcg/mL Patient preference Nasal Neurogenic
nostril once daily
Semax

Injection 5mL at 1000mcg/1mL 0.1mL daily Patient preference Subcutaneous injection Neurorestorative
into the abdomen

Nasal 3mL at 7500mcg/mL One spray into each Patient preference Nasal Neurogenic
nostril once daily
Tesamorelin

Injection 24 vials (lyophilized) 1 (1mg) vial Before bed, 90 minutes Subcutaneous injection Muscle building,
at 1mg/vial 6 days a week after last food intake into the abdomen weight loss

Tesofensine

Capsules 500mcg (30 capsules) 1 capsule daily In the morning Patient preference Weight loss

Thymosin Alpha-1
0.15mL daily or Subcutaneous injection Immune
Injection 5mL at 3000mcg/mL Patient preference
1.5mg twice a week into the abdomen modulation
Thymosin Beta-4
0.25mL daily Subcutaneous injection
Injection 5mL at 3000mcg/mL Patient preference Repair soft tissue
for 20 days into the abdomen
TMB

Insulin resistance,
Capsules 40mg (30 capsules) 40mg twice daily Patient preference Oral
weight loss
TTA/Amlexanox

Capsules 200mg/40mg (30 1 capsule 3 times daily Breakfast, lunch, dinner Oral Insulin resistance,
capsules) weight loss
VIP

One spray into each

Nasal 12mL at 50mcg/mL nostril up to 4 times daily Patient preference Nasal Mold toxicity

Zinc Thymulin

Foam 30mL at 50 mcg/mL 2 pumps (1mL) daily Applied right before bed Foam (for scalp Hair loss
application)

62 Please contact Tailor Made Compounding with any questions about product dosing. 63
 Minnesota

Licensed States

STATES WE ARE
LICENSED IN!
64 65
 POSITIVELY DOWNLOAD
OUR APP TODAY!
DISRUPTING Search “Tailor Made Compounding” in the app store

MEDICINE
USING
INNOVATIVE
TECHNOLOGY
- Quality Assurance - Peptide Therapy
(HPLC - Mass Spectrum)
- IV Therapy
- Education
(Webinars - Workshops) - Sterile
Compounding
- Partnering with Physicians
(Monetize your Practice)
66 67
 Have a question? We have answers!
859.887.0013 | www.tailormadecompounding.com

Management Team
RYAN SMITH
VP OF BUSINESS DEVELOPMENT
EMAIL rs@tailormadecompounding.com CELL 859.797.2983

TORY NEWTON
HEAD OF OPERATIONS
EMAIL tory@tailormadecompounding.com

LESLIE SPARROW
OPERATIONS SPECIALIST/LICENSING MANAGER
EMAIL leslie@tailormadecompounding.com

BLAKE MCLEOD
PHARMACIST
EMAIL blake@tailormadecompounding.com

ALEXIS ELLIOT
PHARAMACIST
EMAIL alexis@tailormadecompounding.com

Customer Care Team

TY SAYLOR
ACCOUNT MANAGER
EMAIL ty@tailormadecompounding.com

NATASHA GARRETT
SERVICE TEAM LEAD
EMAIL natasha@tailormadecompounding.com

CRYSTAL BREWER
PORTAL SUPPORT
EMAIL crystal@tailormadecompounding.com

68